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Background:  Diabetes and hypertension are implicated in the shortened lifespan of patients with 
schizophrenia. While obesity and atypical antipsychotics are well-established risk factors, the 
roles of socio-demographic and lifestyle factors have not been examined systematically. 
Design:  A systematic review examining socio-demographic and lifestyle factors in diabetes and 
hypertension was carried out.  A cross-sectional study examined the associations between socio-
demographic and lifestyle factors, and diabetes and hypertension in patients with schizophrenia, 
their non-psychiatric first degree relatives, and non-psychiatric controls. 
Methods:  The systematic review was carried out using established guidelines.  Cross-sectional 
data from the Diagnostic Interview for Genetic Studies were analyzed to examine associations 
between socio-demographic and lifestyle risk factors, and diabetes and hypertension in the three 
groups.  
Results:  The systematic review based on 26 studies showed a strong effect of age and African-
American race on the prevalence of diabetes.  Age was also associated with the metabolic 
syndrome, although the effect of race was equivocal.  Sex was an effect modifier for diabetes and 
the metabolic syndrome in some, but not all studies, with higher rates in females.   
AN ASSOCIATION OF SOCIO-DEMOGRAPHIC AND LIFESTYLE FACTORS 
WITH DIABETES AND HYPERTENSION IN PATIENTS WITH SCHIZOPHRENIA 
AND RELATED DISORDERS 
Jaspreet S Brar, Ph.D. 
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 v 
Patients with schizophrenia had higher rates of diabetes and hypertension compared to 
controls.  Multivariate analyses that included age, race, sex, years of schooling, marital status, 
occupational status, and living arrangement showed that only increasing age and African-
American race were significant risk factors for diabetes and hypertension. 
Patients with schizophrenia had higher rates of smoking, alcohol and marijuana use 
compared to controls.  The rates of smoking and marijuana use in patients were also higher than 
the rates in their 1st degree relatives.  Multivariate analyses that included age, race, sex and years 
of schooling, failed to show any significant associations for smoking, alcohol or marijuana use 
with diabetes or hypertension.   
Conclusions:  Only established non-modifiable factors, namely age and race, were confirmed as 
risk factors for diabetes and hypertension in the systematic review and cross-sectional study.   
Public Health Significance:  The dissertation confirms the need for developing services for 
minority, mainly African-American, patients with schizophrenia in order to reduce the disease 
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1.0  INTRODUCTION 
1.1 SIGNIFICANCE OF THE PROBLEM 
In 2006, the National Association of State Mental Health Program Directors (NASMHPD) 
conducted a study across 8 states and concluded that patients with severe mental illnesses (SMI 
include schizophrenia and related disorders such as schizoaffective and schizophreniform 
disorders, and bipolar disorders) died approximately 25 years earlier than populations from the 
same states (Parks et al., 2006).  Contrary to popular belief, only a minority (30% to 40%) of this 
excess mortality was due to suicide and injury. The majority (60% to 70%) of premature deaths 
were attributable to chronic medical illnesses, namely cardiovascular diseases, diabetes, 
pulmonary, and infectious diseases. 
Newman and Bland (1991) observed a 20% shorter life span (10 – 15 years) due to 
increased risk for death from medical causes in patients with schizophrenia.  Although several 
other reports also observed shortened lifespan in patients with SMI as a consequence of co-
morbid medical illnesses (Felker et al., 1996), the NASMHPD report highlighted the magnitude 
of the problem by providing empirical estimates of mortality based on comparisons with age- 
and gender-adjusted populations from the state. The medical illnesses specified in the 
NASMHPD report in large part result from modifiable lifestyle risk factors, namely smoking and 
other unhealthy behaviors like poor nutrition and inadequate physical activity, all of which occur 
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in high rates among patients with SMI (Brown et al., 1999). Furthermore, obesity, which occurs 
at alarmingly high rates in patients with SMI, is an important causative factor for the 
development of these medical illnesses (Chawastiak et al., 2009). These illnesses may also be a 
consequence of mental illness-related factors like poor communication and insight about health 
needs, non-adherence to treatment, and geographical factors affecting access (Ryan and Thakore, 
2002).  
High rates of under-diagnosed and under-treated medical problems in patients with SMI have 
been reported that may in part be due to issues related to physical health care (Folsom et al., 
2002). Medical illnesses in this population are more likely to be treated in the acute phase when 
the disease is severe, painful or life threatening, rather than in its early, less severe phase (Munk-
Jorgensen et al., 2000). Consequently, patients with co-morbid medical illnesses have longer 
stays in acute care facilities and a high overall use of inpatient and outpatient services (Kent et 
al., 1995). This disparate use of resources not only strains the healthcare system, but the absence 
of preventative care predicts a poorer prognosis for mentally ill patients with co-morbid medical 
illnesses (Dixon et al., 1999). Physical illnesses also have a detrimental effect on quality of life, 
self-esteem and compliance, thereby compromising the prognosis of the psychiatric illness 
(Dixon et al., 1999). 
1.1.1 Socio-Demographic and Lifestyle Factors 
The role of socio-demographic and lifestyle factors in the risk of developing several medical 
comorbidities is well-established in non-SMI populations.  For example, obesity is associated 
with a higher risk of diabetes, cardiovascular disease, and some cancers (Mokdad et al., 2003).  
The risk for developing these comorbidities also increases with age (Redelmeier et al., 1998). 
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With regard to gender, it is known that the rates of some autoimmune diseases (Sjogren’s 
syndrome and scleroderma), osteoarthritis, and Alzheimer’s disease are higher among women 
than in men, whereas other illness such as epilepsies and aortic aneurysms are more common in 
men (Paeratakul et al., 2002).  Similarly, race and ethnicity exert an influence on the 
development of some medical comorbidities.  Diseases like sickle cell anemia are observed far 
more frequently among persons of African descent, whereas other diseases like cystic fibrosis are 
more common among Caucasians (Kittles and Weiss, 2003).  Socioeconomic factors, namely 
economic impoverishment and employment, contribute significantly to the majority of chronic 
medical comorbidities (Kaplan and Keil, 1993).   
Lifestyle factors such as smoking are linked to illnesses like Chronic Obstructive 
Pulmonary Disease (Fiel, 1996), lung cancer, and heart disease (Ornish et al., 1990).  Other 
lifestyle factors like alcohol consumption increase the risk for liver disease, cardiovascular 
disease, and some cancers (Corrao et al., 2004).  Chronic use of marijuana can increase 
apolipoprotein C-III and increase the risk for myocardial infarction and stroke (Jayanthi et al., 
2008).  
1.1.2 Genetic Factors 
 Genetic factors play an important role in the development of several medical comorbidities.  
Genetic disorders may be x-linked, i.e. involve the sex chromosome or autosomal chromosome 
(dominant or recessive).  The vast numbers of medical comorbidities however are inherited 
through a combination of genetic and environmental factors.  For example, an individual who 
has a family history of diabetes may develop the illness if he/she has additional risk factors such 
as obesity.  Heart disease, stroke, and high blood pressure are other examples of inheritance 
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through dual genetic and environmental mechanisms.  It is therefore important to study the rates 
of medical comorbidities in families in order to tease out the effect of genetic predisposition 
from environmental factors.  First degree relatives that include parents, children, brothers and 
sisters have several factors in common, namely genetic, environmental and lifestyle factors.  
Studying groups of persons with shared genetic and environmental socio-demographic and 
perhaps lifestyle factors is the preferred methodology to control for the risk and bias that may 
result from those factors for the development of medical comorbidities. 
1.1.3 Risk Factors for Medical Comorbidities in Schizophrenia 
 Socio-demographic, lifestyle and genetic factors associated with medical comorbidities 
(described above) are significant determinants of psychiatric disease in patients with 
schizophrenia and related disorders.  Therefore, it may be hypothesized that the development of a 
SMI such as schizophrenia may further exacerbate the effect that socio-demographic and 
lifestyle risk factors may have on the development of medical comorbidities (Cohen, 1993).  
High rates of poverty, smoking, and alcohol consumption are frequent occurrences in these 
populations (Brown et al., 1999).  Although some convergent evidence implicating some of these 
risk factors exists, the studies lack rigor (diagnostic characterization of subjects) and appropriate 
controls (to be discussed later).  Moreover, the role of genetic predisposition for the development 
of medical comorbidities in patients with SRD has not been examined.  A brief review of risk 
factors associated with medical comorbidities is presented.        
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1.1.4 Obesity and Related Factors 
Obesity is an important cause for the development of several medical comorbidities.  Risk 
factors associated with obesity also increase the risk for the development of medical 
comorbidities.  The rates of obesity in the United States (US) have increased exponentially in the 
last 2 decades.  With the exception of Washington, DC and Colorado, 20% or more of the 
population in all states and regions in the US is obese (Body Mass Index = > 30 kg/m2).  The 
rates of obesity in Pennsylvania are 27.4% (Sherry et al., 2010). 
The rates of obesity in patients with SRD have outpaced the national norms (Allison et 
al., 1999).  Although antipsychotics are frequently implicated, higher rates of obesity observed in 
patients with SRD predate the development of these medications (Kraepelin, 1919).  Risk factors 
associated with obesity also increase the risk for the development of medical comorbidities. 
These include atypical antipsychotic medications, diet and nutritional factors and physical 
inactivity. 
1.1.4.1 Atypical Antipsychotic Medications   
With the exception of molindone, all conventional (typical) antipsychotics have been linked with 
weight gain (Heikkinen et al., 1993; Baptista 1999).  However, since the introduction of novel 
(atypical) antipsychotics, which are the treatment of choice for the management of psychosis, the 
rates of obesity have increased substantially.  Most novel (atypical) antipsychotic medications, 
namely risperidone, olanzapine, clozapine and quetiapine, have been shown to cause weight gain 
(Nasarallah, 2003).  Within this class of medication, the propensity for medication-related weight 
gain is highest with olanzapine and clozapine and lowest with risperidone.  The exception to this 
class is aripiprazole, which is weight neutral (Marder et al., 2003). 
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1.1.4.2 Diet and Nutritional Factors 
Poor dietary and nutritional habits have been implicated in the development of obesity in patients 
with schizophrenia (Brown et al.,1999).  Patients with schizophrenia may eat infrequently, have 
a single large meal during the day, choose inexpensive high-calorie foods, and consume large 
quantities of sugar-rich drinks like soda and iced tea (Beebe et al., 2009).  In a nutritional survey 
conducted at the Western Psychiatric Institute and Clinic, it was observed that patients with 
schizophrenia consumed larger quantities and hence more calories of the same foods compared 
to matched controls from the NHANES survey (Strassnig et al., 1993). 
1.1.4.3 Physical Inactivity 
The majority of patients with schizophrenia lead sedentary lives.  This may be related to negative 
symptoms, such as apathy and social withdrawal, or due to medication-related sedation (Brown 
et al., 1999).  Studies that have examined physical activity in patients with schizophrenia using 
pedometers have observed considerably lower activity levels as compared to norms (Kane et al., 
2012).   
1.1.5 Socio-Demographic and Clinical Factors 
Few socio-demographic and clinical correlates of weight gain and obesity have been reported in 
patients with SRD.  Contrary to non-psychiatric population norms, the rates of obesity are higher 
among women than men in patients with schizophrenia (Allison et al., 1999).  In this survey, the 
rates among African-American women were significantly higher than among Caucasian women.  
It is also known that weight gain is precipitous in the first year of treatment with atypical 
antipsychotic medications, with 10 – 15 lbs gain observed in patients treated with clozapine and 
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15 – 20 lbs gain observed in patients treated with olanzapine.  It has also been shown that 
patients who are of normal weight at the beginning of treatment are most likely to gain weight 
with antipsychotic treatment (Kinon et al., 2001).  Furthermore, the rate of weight gain is highest 
in the first 90 days of treatment and may then level off (Kinon et al., 2001). 
1.2 CRITICAL EVALUATION OF THE LITERATURE 
The convergent evidence suggests that patients with SRD have higher rates of medical 
comorbidities, namely diabetes and hypertension, than individuals without psychiatric illness.  
With the exception of a few socio-demographic and clinical factors reviewed earlier that have 
shown an association with some medical comorbidities in patients with SRD, a study of other 
risk factors such as marital status, living arrangement, income/employment, smoking, alcohol 
and marijuana use has not been carried out.  While these risk factors have been examined in non-
psychiatric populations, systematic evidence in patients with SRD is lacking.  Furthermore, with 
regard to the known association of medical comorbidities with other risk factors, studies 
examining such associations in patients with SRD lack rigor because of methodological 
limitations.  Limitations are outlined below: 
1.2.1 Study populations 
Medical comorbidities and their associated risk factors have frequently been reported in hospital-
based samples among individuals who are insured.  It is not known whether this approach may 
have led to a systematic bias in the reported estimates. Estimates from other studies may have 
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been biased as racially homogenous populations were enrolled (Carney, Jones and Woolson, 
2006). 
1.2.2 Selection of controls 
In some studies, samples of patients with SRD were compared with controls from national 
epidemiological surveys such as the NHANES (Strassnig et al., 2003).    Controls enrolled from 
other geographical regions may differ in demographic and social factors from patients with SRD 
leading to systematic biases. 
1.2.3 Ascertainment Bias 
In studies where samples are culled from administrative or claims databases, biases with regard 
to ‘case-finding’ cannot be accounted for.  It is also not possible to determine the extent to which 
rigorous methodology has been applied to the characterization of the psychiatric illness. 
1.3 SIGNIFICANCE OF THE PROPOSED DISSERTATION 
The Substance and Mental Health Services Administration has recognized the increased 
mortality resulting from chronic medical illnesses in patients with severe mental illnesses and is 
spearheading the “10 X 10 Wellness Campaign” to increase life expectancy by 10 years in 10 
years (10 X 10) for people with mental illness.  The following dimensions have been identified 
as possible areas of intervention and improvement to achieve this goal; social, physical, 
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emotional, spiritual, occupational, intellectual, environmental, and financial 
(http://www.promoteacceptance.samhsa.gov/10by10/default.aspx). 
The NIH Roadmap for Medical Research emphasizes that in order to “solve the puzzle of 
complex diseases and conditions” research should be conducted by “filling defined knowledge 
gaps” (Zerhouni, 2003).  The previous research on medical comorbidities in SRD has primarily 
focused on clinical factors, namely obesity-related medical comorbidities, which result from 
treatment with antipsychotic medications.  Thus a “knowledge gap” in this literature exists with 
respect to other factors that may be associated with the development of medical comorbidities in 
patients with SRD.  This dissertation examined whether socio-demographic and lifestyle factors 
were associated with an increased or decreased risk for the development of specific medical 
comorbidities in patients with SRD.  Furthermore, the dissertation also explored how the risk of 
developing medical comorbidities was modified by the genetic predisposition associated with 
several medical comorbidities by comparing differences between the strength and nature of these 
associations in patients with SRD, their non-psychiatric first degree relatives, and unrelated non-
psychiatric controls. 
1.4 STRENGTHS AND WEAKNESSES 
The dissertation examined socio-demographic and lifestyle factors that may have been associated 
with medical comorbidities in patients with SRD.  Three groups, namely patients with SRD, their 
non-psychiatric first degree relatives, and unrelated non-psychiatric controls, were compared.  
These three groups were included in order to examine the following: 
1.) What risk factors are associated with medical comorbidities in patients with SRD? 
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2.) Did risk factors that were associated with medical comorbidities in patients with SRD 
differ from those that were observed in unrelated non-psychiatric control subjects? 
3.) To what extent did genetic predisposition account for the development of medical 
comorbidities in patients with SRD? 
4.) Did first degree relatives of patients with SRD who did not have psychiatric illness have 
similar rates of medical comorbidities and risk factors as patients with SRD and 
unaffected controls?  
1.4.1 Strengths  
This is the first attempt to comprehensively assess many important risk factors that may be 
associated with the development of medical comorbidities in patients with SRD.  A significant 
strength of the study is the uniformity with which the data were obtained.  The Diagnostic 
Interview for Genetic Studies (DIGS; Nurnberger et al., 1994, described later) is an established 
tool for diagnostic characterization of subjects with mental illnesses.  It was administered by 
trained raters across all studies with no systematic changes or modifications from study to study.  
Furthermore, the similarities in the inclusion/exclusion criteria across all studies also increased 
the confidence for pooling these data.  There were no restrictions based on comorbid conditions, 
such as comorbid medical illnesses or comorbid alcohol or substance abuse/dependence, on the 
types of patients who could or could not be enrolled in these studies.  Thus, these broad inclusion 
criteria vastly enhanced the external validity (generalizability) of the sample.  This uniform 
strategy for ascertaining the Axis 1 diagnoses addressed the case-finding bias that was observed 
in the literature.   Another significant strength of the study was the availability of information 
from first degree relatives without psychiatric illness(es).  This allowed for the examination of 
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genetic predisposition as an additional risk for the development of medical comorbidities.  
Lastly, the availability of data from unrelated non-psychiatric controls who were enrolled 
contemporaneously from the same geographical area as patients with SRD or their relatives 
provided a unique opportunity for comparison of rates and risk factors in these groups.  Thus, 
confounding that may have resulted from enrollment of non-contemporaneous controls or those 
derived from national epidemiological surveys was minimized. 
Unlike several studies in the literature, the study sample was heterogeneous with respect 
to the distribution of demographic and social factors.  Thus, the external validity 
(generalizability) of findings from such a sample was likely to be high. 
1.4.2 Weaknesses 
The proposed study has several weaknesses.  First, the study was based on a cross-sectional 
examination of medical comorbidities and risk factors in three groups of subjects.  Given this 
design, no assumptions of causality could be made as temporal precedence could not be 
established.  Rather, the data only showed whether the risk factor(s) are associated with a 
particular medical comorbidity.  Second, the characterization of medical disorders was based 
only on the subject’s self-report.  The diagnoses had not been corroborated or verified.  Studies 
using this methodology usually result in an under-estimate of the outcome (Elliott and Huizinga, 
1989).  Therefore, lower than expected rates of medical comorbidities may have been observed.  
Third, although quite comprehensive in its scope, this study did not address all possible factors 
and mechanisms that may have accounted for the development of medical comorbidities in 
patients with SRD.  Chiefly, a measure of body weight (or BMI) was not available and therefore, 
the role of obesity as a risk factor for the development of some medical comorbidities, for 
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example diabetes and cardiovascular disease, could not be accounted for.  This limitation may 
have affected the validity of the relationship(s) between the other proposed risk factors and 
medical comorbidities because as previously stated, the rates of obesity are quite high in this 
population and body weight is only one of many potential factors that may lead to the 
development of medical comorbidities.  These limitations notwithstanding, the comparison of 
various study groups was likely to have high internal validity because the biases apply to all 
subjects uniformly. 
1.5 HYPOTHESES AND SPECIFIC AIMS 
As part of this dissertation, a systematic review of published literature was carried out in order to 
examine socio-demographic and lifestyle factors (smoking, alcohol and marijuana use) that may 
be associated with diabetes, hypertension or the metabolic syndrome in patients with SRD.  The 
dissertation also examined the associations between 1) socio-demographic factors, and 2) 
lifestyle factors with selected medical comorbidities in patients with SRD enrolled in genetic 
studies carried out at the Western Psychiatric Institute and Clinic, University of Pittsburgh 
School of Medicine, Pittsburgh, PA (hereinafter referred to as probands).  Additionally, these 
associations were examined in non-psychiatric first-degree relatives of the probands and in 
contemporaneously enrolled unrelated non-psychiatric controls from the same geographical 
areas.  The following medical illnesses were included in these analyses; diabetes and 
hypertension.  The specific aims and hypotheses were as follows: 
Specific Aim 1: Examine the rates of hypertension and diabetes in patients with Schizophrenia, 
their 1st degree non-psychiatric relatives, and unrelated non-psychiatric controls. 
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Hypothesis 1:  The rates of hypertension and diabetes are higher in patients with Schizophrenia 
and related disorders compared to 1) their non-psychiatric relatives and 2) unrelated healthy 
controls. 
Specific Aim 2: Compare the associations between socio-demographic risk factors and 
hypertension and diabetes in patients with Schizophrenia, their 1st degree non-psychiatric 
relatives, and unrelated non-psychiatric controls.  
Hypothesis 2:  Similar to associations observed in the general population, socio-demographic 
risk factors namely, age, race, gender, marital status, living arrangement, occupation and 
education are associated with hypertension and diabetes in patients with Schizophrenia and 
related disorders. 
Specific Aim 3: Compare the associations between lifestyle factors and hypertension and 
diabetes in patients with Schizophrenia, their 1st degree non-psychiatric relatives, and unrelated 
non-psychiatric controls.  
Hypothesis 3:  Similar to associations observed in the general population, lifestyle factors 
namely, smoking, alcohol, and marijuana use are associated with hypertension and diabetes in 
patients with Schizophrenia and related disorders. 
1.5.1 Rationale for Selection of Study Groups 
Comparison of patients with SRD and unrelated non-psychiatric controls was carried out to show 
whether the association between the proposed risk factors and medical comorbidities varied in 
groups that were discordant for SRD and did not share genetic predisposition.  Comparison of 
patients with SRD with their first degree non-psychiatric relatives was carried out to show 
whether the association between the proposed risk factors and medical illnesses varied in groups 
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that share a common genetic predisposition for the development of medical comorbidities, as 
well as several socio-demographic factors, but were discordant for the presence of psychiatric 
illness.  Comparison of first degree relatives with unrelated non-psychiatric controls were carried 
out to inform the extent to which family history of psychiatric illness influenced the presence or 
absence of a medical comorbidity in individuals who did not have SRD.        
1.5.2 Data for the Proposed Dissertation 
The proposed dissertation is based on secondary data analysis of four large NIMH-funded 
genetic studies carried out by Vishwajit Nimgaonkar, MD, DPhil and colleagues at the 
University of Pittburgh.  An exempt IRB approval from the University of Pittsburgh for 
secondary analysis of anonymized data was obtained. 
These studies investigated the genetic basis for schizophrenia by enrolling patients with 
schizophrenia, their psychiatrically ill and non-psychiatric first degree relatives, and unrelated 
non-psychiatric controls from the same geographic area as the patients. The Diagnostic Interview 
for Genetic Studies (DIGS) was used to obtain socio-demographic and clinical information for 
diagnostic formulation of all study participants including the proband, their non-psychiatric first 
degree relatives, and unrelated non-psychiatric controls.  The DIGS also elicits information about 
medical comorbidities.  This uniform methodology facilitates the pooling of data in order to 
examine factors associated with medical comorbidities in all groups of interest. Details about the 
four studies are presented below: 
1.) Candidate Gene Alleles: Associations with Schizophrenia (1K02MH000966; 
IRB#9509115): The objective of this study was to identify genetic susceptibility factors 
for schizophrenia using a combination of linkage and association studies in families with 
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one or more members affected with schizophrenia or schizoaffective disorder.  Subjects 
of all races were recruited. 
2.) Genetic Susceptibility in Schizophrenia (1R01MH056242; IRB#:020603):  The objective 
of this study was to identify dopamine (DA) genes that may underlie liability to 
schizophrenia and related psychiatric disorders through analysis of a large sample of 
families with at least one member with schizophrenia or schizoaffective disorder, and an 
additional sample of unrelated control subjects.  Subjects of all races were recruited.  
3.) Schizophrenia Liability Genes among African Americans (1R01MH066263; 
IRB#:020526):  The objective of this eight-institute collaborative study was to identify 
genes that underlie liability to schizophrenia in African American families with at least 
one member with schizophrenia or schizoaffective disorder. 
4.) A Neurobehavioral Family Study of Schizophrenia (1R01MH063480; IRB#:010218):  
The objective of this two-site study (University of Pittsburgh and University of 
Pennsylvania) was to combine genetic and neurobiologic paradigms enabling detection 
and localization of genes that modulate susceptibility to schizophrenia or schizoaffective 
disorder in multiplex, multigenerational Caucasian families. In addition to the patients 
with schizophrenia (probands), only those first degree relatives who did not have 
psychiatric illness were included in the dissertation. 
1.5.3 Diagnostic Interview for Genetic Studies 
The Diagnostic Interview for Genetic Studies (DIGS) developed by the NIMH is a semi-
structured interview for (poly-) diagnostic formulation using standard diagnostic criteria 
(Nurnberger et al., 1994).  It can take 2-3 hours to complete and the time depends upon the 
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extent of the psychopathology and medical comorbidities.  It also enables a detailed assessment 
of course of illness.  The DIGS can be administered by individuals who have experience in 
interviewing and assessing manifest psychopathology.  The kappa coefficients for test-retest 
reliability (4-10 day interval) of the scale for depression, bipolar disorder and schizophrenia, 
were 0.94, 0.96 and 0.75 respectively (Nurnberger et al., 1994). 
The first section of the semi-structured interview (A. Demographics) capture socio-
demographic information and the second section (B. Medical History) captures information 
related to medical comorbidities and smoking.  Alcohol and marijuana use-related information is 
recorded in the I. Alcohol Use and Dependence and J. Drug Abuse and Dependence sections. 
1.5.4 Psychiatric Diagnosis for Case Identification 
Psychiatric diagnosis for case identification was culled from the DIGS for the following DSM-
IV categories for “Schizophrenia and Other Psychotic Disorders (295.xx); 295.30 – Paranoid 
Type, 295.10 – Disorganized Type, 295.20 – Catatonic Type, 295.90 – Undifferentiated Type, 
295.60 – Residual Type, 295.40 – Schizophreniform Disorder, 295.70 – Schizoaffective Disorder 
and 298.9 – Psychotic Disorder NOS.  Other co-morbid Axis 1 diagnoses (for cases of 
‘Schizophrenia’ identified above) were also extracted from the database. 
1.5.5 Plan for Statistical Analysis 
Prior to analyses, distributions of the variables were examined and data transformations done to 
reduce skewness.  Other data reduction techniques including recoding and stratification were 
employed if necessary.  The prevalence rates of diabetes and hypertension were calculated for 
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patients with SRD (probands), their non-psychiatric first degree relatives, and unrelated non-
psychiatric controls and compared across the three groups. 
The associations between demographic factors with diabetes or hypertension were 
examined in the following populations; probands, their non-psychiatric first degree relatives, and 
unrelated non-psychiatric controls. Specifically, the analyses examined whether the rates of 
various medical comorbidities were affected by age, gender, and ethnicity.  Similar analyses for 
examining the association between social factors, namely, marital status, occupation (self, parent 
and head of household), and education were carried out. Similarly, the associations between 
lifestyle factors, namely smoking, marijuana and alcohol use, with diabetes or hypertension were 
examined. 
1.5.6 Outline of the Dissertation 
The dissertation consists of three separate manuscripts: 
Manuscript 1:  A systematic review of the literature examining the association between socio-
demographic and lifestyle factors with diabetes, hypertension and the metabolic syndrome in 
patients with schizophrenia. 
Manuscript 2:  An investigation of the association of socio-demographic factors with diabetes 
and hypertension in patients with schizophrenia and related disorders, their 1st degree relatives 
and unrelated non-psychiatric controls. 
Manuscript 3:  An investigation of the association of lifestyle factors with diabetes and 
hypertension in patients with schizophrenia and related disorders, their 1st degree relatives and 
unrelated non-psychiatric controls. 
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2.0  A SYSTEMATIC REVIEW OF SOCIO-DEMOGRAPHIC AND LIFESTYLE 
FACTORS ASSOCIATED WITH DIABETES, HYPERTENSION AND THE 
METABOLIC SYNDROME IN PATIENTS WITH SCHIZOPHRENIA AND RELATED 
DISORDERS 
2.1 ABSTRACT 
Introduction: Diabetes, hypertension and the metabolic syndrome are important causes of early 
mortality in patients with schizophrenia.  In addition to obesity and iatrogenic effects of atypical 
antipsychotic medications, socio-demographic factors such as age, race, gender, education, 
employment and marital status, and lifestyle factors such as smoking, alcohol and marijuana use, 
may add additional risk for the development of these disorders.  A systematic review was carried 
out to examine the associations between these socio-demographic and lifestyle factors with 
diabetes mellitus, hypertension, and the metabolic syndrome in patients with schizophrenia and 
related disorders. 
Methods: Articles published between 1989 and September 2012 were extracted from Medline 
and PsychINFO using broadly defined search terms.  Relevant studies were selected using 
established methods for systematic reviews, from which primary studies with empirical findings 
were retrieved for further examination.  Wide variations in study populations, designs and 
methodologies of retrieved studies precluded a meta-analytic quantitative summarization of 
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results.  Results were summarized qualitatively for available socio-demographic and lifestyle 
factors associated with diabetes, hypertension and the metabolic syndrome.   
Results: A total of 26 studies formed the basis of the systematic review.  Convergent findings 
suggested that age increased the risk for diabetes mellitus, hypertension, and the metabolic 
syndrome.  African-American race was consistently associated with a higher prevalence of 
diabetes, but its relationship with the metabolic syndrome varied.  Some studies showed higher 
prevalence of the metabolic syndrome in African-American patients, while other studies showed 
higher rates among Hispanic and Caucasian patients.  The results with respect to sex were 
equivocal, with a higher risk of diabetes and the metabolic syndrome for females and a higher 
risk for hypertension for males.  Studies examining other socio-demographic and lifestyle factors 
were either too few or had not been done at all to yield meaningful conclusions. 
Conclusions: Age and African-American race increase the risk for diabetes and hypertension in 
patients with schizophrenia.  The majority of studies that examined the role of sex found that 
female patients were more likely to have higher rates of diabetes.  The role of education, marital 
status, occupation, and living arrangement as effect modifiers could not be established in this 
review as there were too few studies that examined these characteristics.  Similarly, there were 
too few or no studies examining lifestyle factors in diabetic and hypertensive patients with 
schizophrenia to determine their association with diabetes, hypertension, or the metabolic 
syndrome.  Longitudinal studies must include these factors for a comprehensive assessment of 
diabetes, hypertension, and metabolic syndrome risk.  Analyses stratified by important socio-
demographic factors, for example sex, must be carried out in future studies in order to identify 
subgroups at highest risk for developing these disorders.     
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Public Health Significance:  The study confirms the need for additional attention to address the 
high rates of diabetes and hypertension in African-American patients with schizophrenia.   
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2.2 INTRODUCTION 
High rates of chronic medical conditions are associated with increased mortality in patients with 
schizophrenia as compared to the general population (Goldman, 1999).  A recent survey of 
mortality data from state hospitals across 8 states using age and sex-matched controls, showed a 
25 year lifespan gap among patients with schizophrenia and related disorders (SRD) attributable 
mainly to cardiovascular, cerebrovascular and pulmonary diseases (Parks et al., 2006).  
Moreover, treatment outcomes for chronic medical conditions in patients with SRD may be 
further compromised by poor access to physical health care and problems with medication 
compliance (Brown et al., 2000).  Lastly, the high rates of cardiovascular risk factors such as 
obesity, poor nutrition, sedentary lifestyles and smoking in patients with schizophrenia also 
contribute to poor outcomes (Connolly and Kelly, 2005).    
Atypical medication-related adiposity is frequently cited as an important reason for the 
development of several obesity-related chronic illnesses in patients with schizophrenia 
(Wirshing, 2004).  Some, but not all, atypical medications have obesogenic effects that increase 
the likelihood for the development of diabetes and hypertension.  There is also limited research 
to suggest that the medication-induced weight gain and dsyglycemia may be moderated by 
demographic characteristics, making some individuals more susceptible to the development of 
these sequelae (Saddichha et al., 2008).  
Diabetes and hypertension, two prototypical chronic conditions that occur at high rates in 
patients with schizophrenia, have multifactorial etiologies (Hennekens et al., 2005).  Known risk 
factors for the development of these disorders in the general population can broadly be divided 
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into two types; un-modifiable and modifiable.  Un-modifiable factors include demographic 
characteristics such as age, race, sex and family history of diabetes.  Marsh and colleagues 
observed that 20 percent of geriatric patients with schizophrenia had diabetes (Marsh et al., 
1997).  However, other studies have reported higher rates of diabetes among younger and 
middle-aged patients with schizophrenia but not in older patients (Jeste et al., 1996).   The rates 
of cardiovascular diseases are also higher in patients with schizophrenia than in the general 
population (Dixon et al., 1999).  Higher rates of these disorders have been found in older patients 
that also frequently account for medical hospitalization (Sajatovic et al., 1996).   An age-
dependent effect on the prevalence of hypertension has also been shown, although some studies 
have reported lower rates of hypertension, coronary heart disease and congestive heart failure in 
elderly patients with schizophrenia (Larco and Jeste, 1994).   
With regard to gender, some studies have shown higher rates of diabetes in female 
patients compared with males (Philippe et al., 2005).  Rates of the metabolic syndrome are also 
higher in female patients compared to males (McEvoy et al., 2005).  The metabolic syndrome, 
also called Syndrome X, is a clustering of risk factors that increase the risk for coronary artery 
disease, stroke and type-2 diabetes (Alberti et al., 2005).  In order to meet diagnostic criteria for 
the metabolic syndrome as set forth by the National Cholesterol Education Program (Adult 
Treatment Protocol III), three or more of the following criteria must be present; 1) Abdominal 
obesity: Men > 40 inches, Women > 35 inches, 2) fasting triglycerides > 150 mg/dL, 3) high 
density lipoprotein cholesterol (HDL-C): Men < 40 mg/dL, Women < 50 mg /dL, 4) blood 
pressure > 130/85 mm Hg or an antihypertensive medication, and 5) fasting glucose > 110 
mg/dL or on insulin or hypoglycemic medication (Expert Panel on Detection, 2001).  Metabolic 
syndrome was included for this systematic review as both comorbidities of interest, diabetes and 
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hypertension, are part of the cluster that collectively increase the risk for coronary artery disease 
and type-2 diabetes.  Since 2000, there has been a increase in the number of studies examining 
the metabolic syndrome in patients with schizophrenia and related disorders (De Hert et al., 
2009).  It is thus imperative that the metabolic syndrome be included in any comprehensive 
evaluation of cardiovascular risk factors.  Similar to diabetes and hypertension, the rates of the 
metabolic syndrome in patients with schizophrenia are at least 1.5 to 2-fold the rates observed in 
the general population (De Hert et al., 2009).  
Minority patient populations, both African-American and Hispanic, have higher rates of 
diabetes and hypertension compared to Caucasian populations.  A few studies however, have 
shown higher prevalence of the metabolic syndrome among Caucasian patients compared to 
African-American patients.  In a study by Meyers and colleagues, a higher proportion of white 
patients met criteria for the metabolic syndrome compared to non-white patients with 
schizophrenia (61.5% vs 44.6%, p < 0.05; Meyer, Pandina et al., 2005).      
Modifiable factors that afford environmental risk include educational attainment, obesity, 
smoking and alcohol use (Wilson et al., 1998).  Social supports such as marital status and 
solitary living are additional modifiable factors that not only increase the risk for the 
development of chronic medical conditions like diabetes or hypertension, but also impact 
outcomes (Sherbourne and Hays, 1990).    
Whereas an association between antipsychotic medication-related adiposity and diabetes 
and hypertension has been shown in patients with schizophrenia (Citrome et al., 2007), the effect 
of socio-demographic factors, such as age, race, sex, education, marital status and occupation on 
the relationship have not been examined.  Moreover, the contribution of lifestyle factors, namely, 
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smoking, alcohol and marijuana, in the development of these disorders in patients with SRD, 
although suggested anecdotally, remains unclear.   
In the general population, smoking is an independent risk factor for both diabetes and 
hypertension (Rosen et al., 2006; Willi et al., 2009).  Similarly, heavy use of alcohol also 
increases the risk for hypertension (Puddey et al., 1985).  This risk is compounded if alcohol is 
consumed in the absence of food, adding additional vulnerability for patients with schizophrenia 
who have poor dietary habits (Stranges et al., 2004; Peet, 2004).  The role of marijuana use in the 
development of diabetes and hypertension is less clear.  A recent report of an inverse association 
between marijuana use and diabetes is intriguing but requires replication in the general 
population (Rajavashisth et al., 2012).  On the other hand, the relationship between heavy 
marijuana use and the increased risk for myocardial infarction and stroke in the general 
population is well established (Sidney et al., 2002; Frishman et al., 2003). 
The cumulative risk afforded by socio-demographic and lifestyles factors for the 
development of diabetes, hypertension, and the metabolic syndrome in a population of mentally 
ill patients, who have a substantial pre-existing liability for these disorders from psychotropic 
medications, is likely to be high.  It is also essential that the evaluation of socio-demographic and 
lifestyle factors that are associated with diabetes and hypertension be carried out within the 
context of the same study so that confounding factors, if any, are uniformly applied while testing 
all associations.  Given the large numbers of socio-demographic and lifestyle risk factors that 
may be associated with diabetes or hypertension, a study of substantial size where uniform 
methodology has been applied for data collection is ideal.  However, in the absence of such a 
study, a systematic review or a meta-analysis may be carried out by combining and contrasting 
the results obtained from different studies.  Results obtained from multiple studies may either be 
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summarized quantitatively using statistical techniques (Meta-analysis), or summarized 
qualitatively (Systematic review).   
This review examined the relationship between socio-demographic and lifestyle factors 
and diabetes, hypertension, and the metabolic syndrome in patients with schizophrenia and 
related disorders by conducting a systematic review of all available evidence. 
2.3 METHODS 
2.3.1 Search Strategy 
Data for the study were retrieved from Medline and PsychINFO databases using the OVID 
interface.  Studies published between 1989 and September 2012 were included.  The starting 
year 1989 was selected to coincide with the approval of clozapine, the first prototypical 
antipsychotic medication, which also had pronounced obesogenic effects (Choc et al., 1990).  In 
the ensuing period, there has been a renewed interest in examining cardiovascular risk factors 
attributable to the increased risk for development chronic medical conditions.  The systematic 
review is intended to examine socio-demographic (age, race, sex, education, occupation, martial 
status, living arrangement) and lifestyle factors (smoking, alcohol and marijuana use) associated 
with the high rates of diabetes, hypertension and the metabolic syndrome in patients with 
schizophrenia and related disorders. 
Search terms used for the retreival of studies included schizophrenia, schizoaffective 
disorder, schizophreniform disorder, severe mental illness and serious mental illness.  In order to 
identify articles related to diabetes, hypertension, and the metabolic syndrome the following 
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search terms were used; diabetes, hyperglycemia, dysglycemia, metabolic syndrome, syndrome 
X, hypertension,and high blood pressure.  The two searches, articles of schizophrenia and studies 
of diabetes, hypertension and the metabolic syndrome, were combined.  Next, articles that 
addressed socio-demographic and lifestyle factors were extracted using the following terms; age, 
age-adjusted, age-stratified, race, ethnicity, sex, gender, education, schooling, marital status, 
spouse, living arrangement, smoking, nicotine, tobacco, alcohol, ethanol, marijuana, and 
cannabis.  A dataset was created that included articles with schizophrenia, diabetes, hypertension 
or the metabolic syndrome with the articles that addressed any one or more of the socio-
demographic or lifestyle factors.  The title and abstracts of articles to be included were reviewed 
and in the case where it could not be ascertained whether a particular socio-demographic or 
lifestyle factor was examined, the full articles was examined.  In addition, the bibliographies of 
published articles were also examined to include studies that may not have been retrieved 
through the Ovid search.  Articles that included one or more socio-demographic or lifestyle 
factors of interest were selected. 
2.3.2 Inclusion and Exclusion Criteria 
Cross-sectional studies including case-control and retrospective chart reviews and longitudinal 
studies including cohort studies and randomized controlled trials were included. Narrative 
reviews, case reports, commentaries and editorials were excluded from the systematic review as 
were studies published in foreign languages.  Studies on type-1 diabetes, which results from a 
different etio-pathogenic mechanism and has shown an inverse relationship with schizophrenia, 
have not been included in this review (Juvonen et al, 2007). 
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2.3.3 Qualitative Assessment of Studies 
Findings from selected studies were summarized in tables using criteria that represented sample 
size, sample characteristics, type of study, demographic profile and primary finding related to the 
factor of interest.  Results of factors that yielded very few studies were summarized narratively. 
Because of the nature of this study, only the author was involved in searching for and 
retreiving available articles, and culling data to include in the systematic review.  The search for 
retrieval of studies was done at least twice to ensure that the methodology used may be 
reproducible. 
2.4 RESULTS 
2.4.1 Search Results 
 The search results are summarized in Figure 1.   
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Figure 1. Search Results 
 
A total of 186,598 articles were identified for schizophrenia and related disorders and 
705,513 for diabetes or hypertension or the metabolic syndrome using the search terms described 
earlier.  The combination of these two data-sets yielded 2,986 articles.  In a separate search 
10,919,346 articles were identified for any socio-demographic factor of interest and 577,161 for 
any lifestyle factor.  Combination of the socio-demographic and lifestyle data-sets with the 
schizophrenia plus diabetes or hypertension data-set yielded 1756 articles.  
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After removing duplicates, review articles, case reports, editorials and commentaries and 
limiting the search to English language articles published between 1989 to September 2012, 767 
articles remained.  As the search targeted title and abstract fields instead of keywords, all 
publications in which an assortment of search terms appeared were retrieved. The majority of 
these articles did not have any empirical measurement of any of the socio-demographic or 
lifestyle factors of interest, or cases with diabetes, hypertension or the metabolic syndrome.  
However, from this data-set, only articles that included an analytic examination of any one or 
more of the socio-demographic or lifestyle factors in patients with schizophrenia, hypertension 
or the metabolic syndrome, were selected. 
A total of 26 studies were included in the systematic review.  No additional articles were 
identified by reviewing the bibliographies of review articles and published studies that were not 
included in the original searches.      
2.4.2 Systematic Review of Socio-Demographic Risk Factors 
Effect of Age: A total of 10 studies addressed the association between age and diabetes, 
hypertension or the metabolic syndrome in patients with schizophrenia and related disorders.  







Table 1. Effect of Age 










Studies of Diabetes 
Dixon et al., 
2000 
20967 I-P,  
O-P 









et al., 2003 
194 O-P C-S 55.5 + 
12.7 
Unknown 80 *Higher rates in 
all age strata but 
lower in > 70 
Voruganti et 
al., 2007 
1123 O-P C-S 44.2 + 
12.6 
82/18 63 Positive 
association with 
age 
Chien et al., 
2009 
4417 ND C-S S-d Taiwanese 55 *Higher rates in 
all age strata but 
lower in > 70  
Okumura et al., 
2010 
3489 ND C-S 44.5 + 
14.3 
Japanese 49 *Higher rates in 
all age strata 
Hsu et al., 
2011 
3150 ND C-S S-d Taiwanese - *Higher rates in 
all age strata 
Studies of the Metabolic Syndrome 
Straker et al., 
2005 
89 I-P C-S 39.8+ 
15.3 
32/28/20 50 Positive 
association 
McEvoy et al., 
2005  
689 I-P,  
O-P 
Long 40.4 + 
11.2 




102 I-P Long 38 + 
10.8 
51/49 50 Positive 
association 
Studies of Hypertension 
Lan et al., 2012 1030 I-P C-S 48 + 
12.2 
Taiwanese 60 *Higher rates in 
all age strata 
UNK = Unknown;    N = Sample Size;  S-d:  (Age) Stratified in Deciles,    
I-P = Inpatient;  O-P = Outpatient;  ND = National Database 
C-S = Cross-Sectional including Case Control studies 
Long = Longitudinal including cohort studies and randomized controlled trials 
DM = Diabetes,  HT = Hypertension,  MS = Metabolic Syndrome 
Race % Cauc / A-A / Other = Percent of Caucasian / African-American / Other. 
(In the case only two numbers are presented = Caucasian / African-American) 
Sex % M = Percent of Males 
* = Incremental increase, i.e. a positive relationship between 2 variables  
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Increasing age was associated with incrementally higher risk for diabetes, the metabolic 
syndrome and hypertension.   Studies that compared these associations to those observed in the 
general population also showed much higher rates of diabetes among younger age groups in 
patients with schizophrenia (Subramaniam et al., 2003, Chien et al., 2009).   These studies also 
observed lower prevalence rates among older patients greater than 70 years of age compared to 
population norms.  Although it is unclear why such trends exist, it may be the result of a 
‘survivor effect’ where healthy individuals are more likely to survive into their older years 
compared with unhealthy individuals who die earlier (Richardson et al., 2004).   
An incremental association with age was also observed for hypertension and the 
metabolic syndrome (Lan et al., 2012; McEvoy et al., 2005).  These trends with age were present 
in all populations that included European, American, Taiwanese and Japanese samples.  Studies 
that presented age-corrected prevalence rates were not reviewed as the relationship between age 
and diabetes, hypertension or the metabolic syndrome could not be ascertained (Liao et al, 2011). 
Effect of Race:  A total of 17 studies addressed the association between race and diabetes or 
hypertension or the metabolic syndrome in patients with schizophrenia and related disorders.  









Table 2. Effect of Race 







Studies of Diabetes 
Dixon et al., 2000 20967 I-P, 
O-P 




Higher in A-A 
Regenold et al., 2002 243 I-P C-S 49 / 51 35 No difference 
Subramaniam et al., 
2003 
194 O-P C-S Unknown 80 No association 
with Asian 
ethnicities 
Sernyak et al., 2003 121 O-P Long 90 / 10 9 Higher in A-A 
Kreyenbuhl et al., 2006 143 O-P C-S 57 / 43 52 Higher in 
nonwhites 
Ramaswamy et al, 
2007 
140951 Med Long 77 / 15 /8 47 Higher in A-A 
Studies of the Metabolic Syndrome 
Basu et al., 2004 33 O-P C-S 61 / 36 / 3 51 No differences 
Kato et al., 2004 48 O-P C-S  25/ 10 / 65 50 Higher in 
Hispanics 
McEvoy et al., 2005 689 I-P,O-P Long 60 / 40 74 Higher in A-A 
Straker et al., 2005 89 I-P C-S 52 / 28 / 20 50 No Differences 
Lambert et al., 2005 3663 Med Long 49 / 21 / 30 47 Higher in A-A and 
Hispanics 
Meyer et al., 2005 (a) 1231 I-P, 
O-P 
C-S 74 / 26 59 Higher in Whites 
Meyer et al., 2005 (b) 121 O-P C-S 49 / 51 54 Higher in Whites 
Lamberti et al., 2006 93 O-P C-S 80 / 20 67 No differences 
Bermudes et al., 2006 102 I-P Long 51 / 49 50 Higher in 
Caucasians 
Corell et al., 2008 111 I-P C-S 84 / 16 49 No Differences 
Meyer et al., 2009 314 O-P Long 57 / 27 / 16 70 Higher in A-A 
Rivas-Vazquez et al., 
2011 
122 O-P C-S 80% 
Hispanics 
72 Highest in Cuban 
Americans 
Studies of Hypertension 
McEvoy et al., 2005 689 I-P,O-P Long 60 / 40 74 Higher in A-A 
N = Sample Size;  S-d:  (Age) Stratified in Deciles,    
I-P = Inpatient;  O-P = Outpatient;  ND = National Database 
C-S = Cross-Sectional including Case Control studies, Long = Longitudinal studies 
DM = Diabetes,  HT = Hypertension,  MS = Metabolic Syndrome, DKA = Diabetic Ketoacidosis 
Race % Cauc / A-A / Other = Percent of Caucasian / African-American / Other. 
(In the case only two numbers are presented = Caucasian / African-American) 
Sex % M = Percent of Males 
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Most cross-sectional studies showed higher rates of diabetes in African-American 
patients with schizophrenia.  African-American patients also had higher odds for developing 
diabetes following antipsychotic treatment (Lambert et al., 2005).  Studies with diverse 
populations including Medicaid and Medicare recipients consistently show higher rates of 
diabetes among African-American patients with schizophrenia (Dixon et al., 2000).  These racial 
differences were also observed in the prevalence of undiagnosed diabetes and diabetic 
ketoacidosis (Sernyak et al., 2003, Ramaswamy et al., 2007). 
Racial differences were less consistent for association with the metabolic syndrome, with 
some studies showing higher rates among African-American patients (Meyer et al., 2009, 
Lambert et al., 2005) or Hispanic patients (Kato et al., 2004, Rivas-Vazquez et al., 2011), with 
other studies showing higher prevalence among Caucasian patients (Meyer et al., 2005(a); Meyer 
et al., 2005(b), Bermudes et al., 2006).  Some studies also failed to show any racial differences in 
the prevalence of the metabolic syndrome (Lamberti et al., 2006, Corell et al., 2008).  With 
regard to hypertension, only one study presented racial differences with higher rates among 
African-American patients (McEvoy et al., 2005).   
Effect of Sex:  A total of 12 studies addressed the association between sex and diabetes or 
hypertension or the metabolic syndrome in patients with schizophrenia and related disorders.  






Table 3. Effect of Sex 
Study N Sample Design Race % 
Caucasian / A-





Studies of Diabetes 








Higher in females 
Subramaniam et 
al., 2003 
194 O-P C-S Unknown 80 No differences  
Voruganti et al., 
2007 
1123 O-P C-S 82 / 18 63 No differences 
Chien et al., 2009 4417 ND C-S Taiwanese 55 Higher in females  
Okumura et al., 
2010 
3489 ND C-S Japanese 49 Higher in Males 30-
49 and females 40-59 
Hsu et al., 2011 3150 ND C-S Taiwanese 50 Higher in females 
Studies of the Metabolic Syndrome 
McEvoy et al., 
2005 
689 I-P,  
O-P 
Long 60 / 40 74 Higher in females  
Straker et al., 
2005 
89 I-P C-S 52 / 28 / 20 50 No differences 
Meyer et al., 
2005 (a) 
1231 I-P,  
O-P 
C-S 74 / 26 59 Higher in females 
Meyer et al., 
2005 (b) 
121 O-P C-S 49 / 51 54 No differences 
Corell et al., 2008 111 I-P C-S 84 / 16 49 No differences 
Studies of Hypertension 
Lan et al., 2012 1030 I-P C-S Taiwanese 60 Higher in males 
N = Sample Size;  S-d:  (Age) Stratified in Deciles,    
I-P = Inpatient;  O-P = Outpatient;  ND = National Database 
C-S = Cross-Sectional including Case Control studies 
Long = Longitudinal including cohort studies and randomized controlled trials 
DM = Diabetes,  HT = Hypertension,  MS = Metabolic Syndrome 
Race % Cauc / A-A / Other = Percent of Caucasian / African-American / Other. 
(In the case only two numbers are presented = Caucasian / African-American) 
Sex % M = Percent of Males 
DKA = Diabetic Ketoacidosis 
 
About half the studies that examined gender differences in patients with schizophrenia 
found higher prevalence of diabetes and the metabolic syndrome in female patients (McEvoy et 
al., 2005, Chein et al., 2009; Hsu et al., 2011, Lan et al., 2012).  The remaining studies did not 
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find gender differences.  Larger gender differences were also observed in Asian populations.  
The rates of diabetes among women with schizophrenia (10.3%) were almost twice the rates 
among men (5.9%; Chien et al., 2009) and 1.5 times higher than the rates among women in the 
general population (Hsu et al., 2011). 
Only one study examined gender differences in the prevalence of hypertension and 
observed higher rates among male patients (Lan et al., 2012). 
Effect of Education:  Only three studies examined the relationship between educational status 
and the prevalence of diabetes in patients with schizophrenia.  Lower education was associated 
with a higher risk of having diabetes (Dixon et al., 2000, Suvasaari et al., 2008).  The third study 
did not find such an association (Voruganti et al., 2007).  
Effect of Employment:  Occupation or employment status as a risk factor for diabetes, 
hypertension or the metabolic syndrome in patients with schizophrenia was not examined in any 
of the studies reviewed. 
Effects of Marital Status and Living Arrangement: Only one study examined marital status and 
found that the rates of diabetes were almost two-fold among patients who were ‘ever married’ 
compared to those who were ‘never married’ (Dixon et al., 2000) .  In one study, independent 
housing, i.e. living on one’s own, did not show any association with diabetes in patients with 
schizophrenia (Voruganti et al., 2007). 
Effects of Lifestyle Factors: None of the studies included in the review examined the 
relationships between smoking or marijuana use and diabetes, hypertension or the metabolic 
syndrome in patients with schizophrenia.  Two studies examined alcohol use; one showed a 
higher odds of having diabetes with alcohol consumption (Suvasaari et al., 2008) and the other 
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showed no relationship of alcohol with the metabolic syndrome in patients with schizophrenia 
(Meyer, Nasrallah et al., 2005). 
2.4.3 Subgroup and Sensitivity analysis 
Given the variations in sampling, design and methodology, a sensitivity analysis was not carried 
out.  However, comparison of broadly defined subgroups, for example, inpatient vs. outpatient 
studies, or cross-sectional vs. longitudinal studies, revealed essentially similar results. 
2.4.4 Publication Bias 
Publication bias cannot be ruled out because unpublished reports and studies printed in foreign 
languages were not included.  A funnel plot, a graphical technique used to assess publication bias 
(Light and Pillemer, 1984), was not constructed as there were marked dissimilarities in the 
methodologies and the resulting effect sizes for associations observed from different studies. 
2.5 DISCUSSION 
The systematic review included 26 studies on diabetes, hypertension and the metabolic syndrome 
in patients with schizophrenia.  Age, race and sex were the most frequently investigated socio-
demographic factors.  Convergent findings suggested that age increased the risk for diabetes 
mellitus, hypertension and the metabolic syndrome in patients with schizophrenia and related 
disorders.  African-American compared to Caucasian race was consistently associated with a 
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higher prevalence of diabetes but its relationship with the metabolic syndrome varied.  Although 
a majority of studies trended towards higher rates for the metabolic syndrome in minority 
populations, several studies failed to find these trends.  Female sex also emerged as a significant 
effect modifier associated with higher rates of co-occurring diabetes or the metabolic syndrome 
in some, but not all, studies.  The findings with regard to age and race were robust and did not 
change based on patient status, inpatient or outpatient, or study design, cross-sectional or 
longitudinal.  No conclusions could be drawn for other social or lifestyle factors because of the 
virtual lack of studies that examined these characteristics. 
2.5.1 Diabetes, Hypertension and the Metabolic Syndrome in Schizophrenia 
Higher rates of diabetes and glucose intolerance were reported in patients with schizophrenia 
prior to the introduction of antipsychotic medications (Raphael and Parcels, 1921).  The rates of 
diabetes increased exponentially after the introduction of the first atypical antipsychotic 
medication clozapine in 1989 (Safferman et al., 1991).  Several other atypicals have been 
introduced subsequently, most of which, with the exception of a few, have varying degrees of 
propensity to cause weight gain, insulin resistence and diabetes (McIntyre et al, 2001).  
Therefore, this review was limited to an examination of risk factors associated with diabetes, 
hypertension and the metabolic sydrome in the ‘new’ era of pharmacotherapy where atypical 
antipsychotic medications are the mainstay of treatment, and estimates of obesity and its related 
sequalae, namely diabetes, hypertension and the metabolic syndrome, have been examined 
systematically using established diagnostic criteria.  
Several studies have shown high rates of hypertension in patients with schizophrenia 
(Hennekens 2007). In a survey of 101 long-term mentally ill adults, Kendrick and colleagues 
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found that about 25 percent of patients were obese, about 50 percent were smokers and about 10 
percent were hypertensive (Kendrick, 1996). Corell and colleagues (2008) observed that 60% of 
patients who met the criteria for the metabolic syndrome had hypertension (Corell et al., 2008).  
In addition to adiposity, treatment with psychotropic medications also increases the incidence of 
hypertension (McEvoy et al., 2007).  A third of patients in the CATIE Study were hypertensive, 
of which only 37.6% were receiving treatment (Nasarallah et al., 2006).  
Some studies have failed to show an increased risk for hypertension in patients with 
schizophrenia (Cohn et al., 2004). In a study using data extracted from the Danish Psychiatric 
Central Research Register, higher rates for hypertension were observed among patients with 
bipolar disorder and anxiety disorders but not among patients with schizophrenia (Johannessen et 
al., 2006).  Studies that report lower rates of hypertension in schizophrenia are usually associated 
with under-diagnosis secondary to a lack of awareness by patients and care providers (Munk-
Jorgensen et al., 2000). 
2.5.2 Effect of Age, Race and Sex 
The effect of age on the risk for diabetes and hypertension in the general population is well 
established.  A higher number of medical comorbidities have been observed in older patients 
with schizophrenia (Jeste et al., 1996).  The effect of age on the incrementally higher risk for 
diabetes has been demonstrated in patients with schizophrenia treated with atypical antipsychotic 
agents (Basu and Meltzer, 2006). In studies that have examined stratified age groups, age-
specific prevalence rates of diabetes increased steadily from 4% in the group aged 30 to 39 years 
to 17.3% in the group aged 40 to 49, to 50.0% in the group aged 50 to 59% (Subramanium et al. 
2003). 
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In patients with schizophrenia, higher rates of obesity and related disorders are seen in 
minority populations (Kumunyika, 2012).  The higher risk for developing medical comorbidities 
in racial minorities stems from several physiological and environmental factors.  In addition to 
genetic factors, poor access to care, low health literacy and cultural competence, socio-economic 
factors, and diet play an etiological role (Liem et al., 1978).  An additive risk model for diabetes 
that includes ethnicity, family history of diabetes, history of glucose dysregulation and pre-
existing hypertension has also been proposed (Lindenmayer et al., 2001). 
Higher levels of insulin resistance, a precursor to the development of diabetes, have been 
observed in women compared with men in the general population (Mittendorfer, 2005).   
Furthermore, the risk for developing coronary artery disease is also higher among diabetic 
women than diabetic men in the general population (Cubbon et al., 2007). Among patients with 
schizophrenia, women are also more likely than men to gain weight with antipsychotic treatment 
(Covell et al., 2004).  The CATIE trial showed higher rates of the metabolic syndrome in women 
(52%) compared to men (36%; McEvoy et al., 2005).  In a study not included in the systemic 
review because it compared diabetic patients with schizophrenia to diabetic patients without 
schizophrenia, it was observed that patients with schizophrenia were 10 years younger and more 
likely to be female with a higher representation of African-American patients (Kreyenbuhl et al., 
2010). 
2.5.3 Effect of Social and Lifestyle Factors 
Poor social supports and solitary living are related to poor psychiatric outcomes in patients with 
severe mental illnesses (Liem and Liem, 1978).  It may be speculated that patients who are 
unmarried or live by themselves have higher rates of chronic medical conditions.  Among social 
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support deficits,  living alone is the strongest factor associated with poor adherence and poorer 
physical quality of life in patients with schizophrenia (Suttajit and Pilakanta, 2010; Kilian et al., 
2001). A systematic evaluation of these risk factors has not been carried out so far.  Furthermore, 
despite the high rates of unemployment in patients with mental illness (Strum et al., 1999), an 
association with co-occurring medical conditions has also not been demonstrated. 
It has been speculated that the high rates of cardiovascular illnesses in patients with 
schizophrenia may be associated with various risk factors, for example, smoking, alcohol use, 
poor diet, and lack of exercise (Davidson, 2002; Ryan and Thakore, 2002).  Whereas moderate 
alcohol use has been shown to be cardio-protective, heavy use increases the risk for 
hypertension, coronary artery disease, and ischemic stroke in the general population (Cargiulo, 
2007). Heavy use of alcohol increases cardiovascular risk by exerting its effects on the 
sympathetic nervous system (Randin et al., 1995).  The systematic review did not include 
sufficient amount of empirical evidence to examine whether alcohol was a risk factor for 
diabetes, hypertension or the metabolic syndrome in patients with schizophrenia and related 
disorders.  With regard to marijuana, longitudinal studies have shown that the risk for developing 
schizophrenia increases with marijuana use in a dose dependent manner (Andreasson et al., 
1987).  Heavy marijuana use is known to increase cardiovascular risk in the general population 
(Aryana and Williams, 2007).  However, the risk attributable to marijuana use for the 
development of medical comorbidities in patients with schizophrenia has not been examined. 
2.5.4 Effect of Socio-Demographic and Lifestyle Factors on Mortality 
Medical illnesses in this population are more likely to be treated in the acute phase when the 
disease is severe, painful or life threatening, rather than in its early, less severe phase (Munk-
 42 
Jorgensen et al., 2000). Consequently, patients with co-morbid medical illnesses have longer 
stays in acute care facilities and a high overall use of inpatient and outpatient services (Kent et 
al., 1995). This disparate use of resources not only strains the healthcare system, but the absence 
of preventative care bodes for a poorer prognosis for mentally ill patients with co-morbid 
medical illnesses (Dixon et al., 1999). Physical illnesses also have a detrimental effect on quality 
of life, self-esteem and compliance thereby compromising the prognosis of the psychiatric illness 
(Dixon et al., 1999).  
Kelly and colleagues (2011) observed that cardiac causes most frequently accounted for 
mortality among smokers with schizophrenia.  The types of cardiovascular disorders however, 
were not enumerated.   A recent meta-analysis concluded that smoking was associated with poor 
psychiatric outcomes but did not examine whether these outcomes were mediated by the 
development of chronic medical disorders (Cerimele and Katon., 2012).   
Mortality among diabetic patients with schizophrenia is associated with age, low use of 
primary care services, male gender, and being unmarried (Copeland et al., 2009).  Mortality 
associated with cigarette smoking increases with age and is higher in males (Kelly et al., 2011). 
Smoking, diabetes and hypertension were associated with an increased 10-year cardiovascular 
risk (Goff et al., 2005).  Birkenas and colleagues observed high rates of age-adjusted 
cardiovascular risk parameters despite higher levels of education in patients with schizophrenia 
compared to the general population (Birkenas et al., 2007).  These illnesses may also be a 
consequence of mental illness-related factors like poor communication and insight about health 
needs, non-adherence to treatment, and geographical factors affecting access to care (Ryan and 
Thakore, 2002). High rates of under-diagnosed and under-treated medical problems in patients 
with severe mental illnesses have been reported that may in part be due to issues related to 
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physical health care (Folsom et al., 2002). In the CATIE trial, the rate of diabetes under-
treatment in non-white women (50%) was considerably higher compared to the undertreatment 
rate in non-white men (18%, Nasarallah et al., 2006). 
2.5.5 Limitations and Future Directions 
This review has several limitations.  Antipsychotic medication use, an important factor for the 
development of diabetes, hypertension and the metabolic syndrome in patients with 
schizophrenia, was not included in this review.  Although medications have a significant role to 
play in the development of both diabetes and hypertension, the majority of studies only consider 
the antipsychotic used at the time of enrollment, ignoring the cumulative exposure that 
medications may have had over their lifetime.  Thus, in the absence of lifetime antipsychotic 
exposure, knowledge of current medications is minimally useful.  The following factors that are 
closely linked with diabetes, hypertension and the metabolic syndrome were not included in this 
review:  measure of adiposity, measure of physical inactivity, diet and nutrition, and family 
history of diabetes or hypertension.  Metabolic syndrome is fueled by these risk factors that are 
known to cluster in patients with schizophrenia (McCreadie, 2003). 
It is important to note that that studies of diabetes, hypertension, and the metabolic 
syndrome may not be comparable because of changes in the diagnostic criteria for these 
conditions.  For example, the change from the standard 75 mg oral glucose tolerance test to 
fasting glucose and more recently to glycosylated hemoglobin (HbA1c) may account for 
differences in the rates of diagnosed diabetes (Jorgensen et al., 2010).   
Despite the limitations, this review draws renewed attention for health services and 
policy plannning with the intent to create preventative services for racial minorities to minimize 
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poor outcomes associated with chronic medical conditions such as diabetes and the metabolic 
syndrome.  In keeping with the goals of the SAMHSA 10 X 10 campaign, a pre-emptive 
approach for providing integrated services that include special programs to address behavioral 
risk factors such as obesity, physical inactivity and smoking will go a long way in reducing the 
morbidity and mortality associated with co-occurring medical disorders in patients with 
schizophrenia. 
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3.0  AN ASSOCIATION OF SOCIO-DEMOGRAPHIC CHARACTERISTISTICS 
WITH DIABETES AND HYPERTENSION IN PATIENTS WITH SCHIZOPHRENIA 
AND RELATED DISORDERS 
3.1 ABSTRACT 
Introduction:  Socio-demographic risk factors associated with diabetes and hypertension in 
patients with schizophrenia in comparison with contemporaneously enrolled non-psychiatric 
healthy controls have not been investigated systematically.  Furthermore, the effect of family 
history of schizophrenia on the prevalence of diabetes and hypertension is not known.  A 
retrospective and cross-sectional study with pooled data from 4 major genetic studies was carried 
out to ascertain the prevalence rates of diabetes and hypertension in patients with schizophrenia, 
their non-psychiatric unaffected 1st degree relatives, and unrelated healthy controls and to 
examine the association of socio-demographic factors with both diabetes and hypertension. 
Methods: Data were extracted from the Diagnostic Interview for Genetic Studies (DIGS) 
questionnaire, which was used for diagnostic formulation of all cases.  Data for diabetes and 
hypertension were extracted from text fields using a large set of search terms.  The rates of 
diabetes and hypertension in the three study groups were compared using contingency statistics.  
Associations between socio-demographic risk factors, namely age, race, sex, marital status, 
living arrangement, years of schooling and occupation, and diabetes or hypertension were 
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examined in each study group separately and in the combined sample using multivariate logistic 
regression analysis.  Stepwise regression with backward elimination was used to find the best 
fitting model. 
Results: The rates for diabetes in patients with schizophrenia, their first degree relatives and 
healthy controls were 10.6%, 9.1% and 6.5%, respectively, and for hypertension were 17.8%, 
8.6% and 9.5%, respectively.  The rates for diabetes and hypertension were significantly higher 
in patients with schizophrenia compared to healthy controls.  The rates for hypertension were 
also higher for patients compared to their 1st degree relatives.  All study groups showed higher 
rates of diabetes and hypertension among African-American subjects compared to Caucasian 
subjects.  Multivariate analyses showed that of all socio-demographic factors examined, only 
increasing age and African-American race were significant risk factors for diabetes and 
hypertension.  In addition, being disabled was a significant risk factor for diabetes but not for 
hypertension.       
Conclusions: Similar to previous studies, the roles of increasing age and African-American race 
as significant risk factors for diabetes and hypertension in all study groups were confirmed.  The 
multivariate analyses failed to show higher rates for both disorders among 1st degree relatives 
compared to controls, suggesting that a family history of schizophrenia did not confer a higher 
risk for the development of either disorder.  Sex, marital status, years of schooling, and living 
arrangement were not associated with either diabetes or hypertension in any group.   
Public Health Significance:  Pursuant to the SAMHSA 10 X 10 Wellness campaign, these 
results underscore the need for heightened awareness and resource allocation for African-
American patients with schizophrenia in order to reduce diabetes and hypertension-related 
mortality in this underserved population. 
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3.2 INTRODUCTION 
Latent genetic, lifestyle and socio-demographic factors mediate the clustering of diabetes and 
hypertension (Whiting et al., 2010; Carmelli et al., 1994).  These two disorders affect the same 
target organs increasing the risk for developing coronary artery disease, stroke, peripheral 
vascular disease, heart failure, and eye and kidney damage.  In a medically underserved 
population such as patients with serious mental illness, poor outcomes for these two disorders 
frequently result from inadequate treatment and management and non-treatment related logistic 
factors (Nasrallah et al., 2006).  These disorders also account for the excess mortality in patients 
with schizophrenia and related disorders (Brown, 1997; Brown et al., 1999).   
3.2.1 Diabetes in Schizophrenia 
Similar to the rates in the US population, the rates of diabetes in patients with schizophrenia have 
increased substantially in the last few years (Schoepf et al., 2012).  These high rates of diabetes 
mimic the high rates of obesity observed in schizophrenia patients treated with atypical 
antipsychotic medications, with the greatest risk afforded by olanzapine and clozapine and the 
lowest by aripiprazole (Lindenmeyer et al., 2003; VanWinkel et al., 2008).  Although most risk 
factors that are associated with obesity may also be applied to diabetes, the disorder may also 
result from mechanisms that are independent of adiposity (Bushe and Holt, 2004).  Atypical 
antipsychotic medication may interfere with the action of the glucose transporter protein or may 
cause hyperglycemia by antagonism of the serotonin 5-HT1A receptor (Dwyer et al, 1999; 
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Liebzeit et al., 2001).   There are several case reports describing the rapid onset of diabetic 
ketoacidosis (DKA) in schizophrenia patients who began treatment with an atypical 
antipsychotic medication (Jin, Meyer and Jeste, 2002).  The etio-pathogenesis of DKA in these 
cases is poorly understood, although the direct effect of the medication on beta-cell function has 
been proposed as a possible mechanism (Cohen et al., 2006).    
The socio-demographic and clinical risk profile for diabetes to a large extent parallels 
that for obesity.  Factors that may increase the risk for diabetes include ethnicity with a higher 
risk in non-white populations, history of gestational  diabetes and history of delivering a baby > 
9 pounds, hypertension: BP > 140/90 mm Hg, dyslipidemia: HDL-C < 35 mg/dL or triglycerides 
> 250 mg/dL, and smoking (Wannamethee et al., 1998).  However, these factors have not been 
examined in schizophrenia patients with diabetes. 
Genetic factors also play an important role in the development of diabetes.  First degree 
relatives of persons with diabetes are 2 to 3 times more likely to develop diabetes than those 
without (Tarn et al., 1988).  Interestingly, a higher rate of diabetes has been observed in first 
degree relatives of patients with schizophrenia than the rates of diabetes among first degree 
relatives of non-schizophrenic persons suggesting that a genetic commonality may exist in the 
inheritance for these two disorders (Mukerjee et al., 1996).   
3.2.2 Cardiovascular Diseases in Schizophrenia 
The rates of several cardiovascular disorders, for example atherosclerotic coronary artery 
disease, angina, and hypertension, occur at higher rates in patients with schizophrenia than in the 
general population (Hennekens et al., 2005).  In fact, the steady increase in mortality from 1976 
to 1995, with the highest increase in the last 5 year period, is attributed to cardiovascular causes 
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in patients with schizophrenia and related disorders (Osby et al., 2000).  Similar to the risk for 
diabetes, the risk for developing these cardiovascular disorders also increases with obesity.  In 
addition, atypical antipsychotic medications may also increase the risk for the development of 
hyperlipidemias through both adiposity-mediated and direct mechanisms (Koro et al., 2002).  
Furthermore, cardiac rhythm abnormalities, particularly those arising from Q-wave changes or 
QT interval prolongation, have been reported in association with certain atypical antipsychotic 
agents, for example ziprasidone (Taylor, 2003). 
3.2.3 Socio-Demographic Factors for Diabetes and Hypertension 
The role of socio-economic factors such as low educational attainment and unemployment, 
which are associated with chronic diseases such as diabetes and hypertension (Whiting et al., 
2010), and are commonly observed in patients with schizophrenia, have not been investigated.  A 
genetic connection between schizophrenia and some medical disorders also has been proposed 
but not investigated (Newman et al., 1987; Dixon et al., 2000).  Furthermore, a systematic review 
that was conducted as part of this dissertation showed that there were either too few or no studies 
that examined the roles of education, marital status, occupation and living arrangement as effect 
modifiers for diabetes and hypertension in patients with schizophrenia. 
 
3.2.4 Hypotheses 
This study examines the rates of diabetes and hypertension in three groups; patients with 
schizophrenia, their unaffected (non-psychiatric) first-degree relatives (including siblings and 
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parents), and contemporaneously enrolled unrelated and unaffected controls.  The associations 
between socio-demographic factors, such as age, race, gender, years of education, marital status 
and occupation, and diabetes and hypertension in the three study groups is also examined.  It is 
hypothesized that the rates of hypertension and diabetes are higher in patients with 
Schizophrenia and related disorders compared to their non-psychiatric 1st degree relatives and 
unrelated healthy controls.  Furthermore, similar to associations observed in the general 
population, socio-demographic risk factors namely, age, gender, ethnicity, marital status, living 
arrangement, occupation and education are likely to be associated with hypertension and diabetes 
in patients with schizophrenia and related disorders and their first degree relatives.  
3.3 METHODS 
3.3.1 Data for the Study 
Data for this study were culled from four large NIMH-funded genetic studies (1. Candidate Gene 
Alleles: Association with Schizophrenia (1K02MH000966), 2. Genetic Susceptibility in 
Schizophrenia (1R01MH056242), 3. Schizophrenia Liability Genes among African-Americans 
(1R01MH066263), and 4. A Neurobehavioral Family Study of Schizophrenia 
(1R01MH063480)) conducted at the Western Psychiatric Institute and Clinic, University of 
Pittsburgh School of Medicine, Pittsburgh, PA.  An exempt IRB approval from the University of 
Pittsburgh for secondary analysis of anonymized data was obtained.  These studies investigated 
the genetic basis for schizophrenia by enrolling patients with schizophrenia, their non-psychiatric 
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first degree relatives, and unrelated non-psychiatric controls from the same geographic area as 
the patients.  
3.3.2 Diagnostic Interview for Genetic Studies 
The Diagnostic Interview for Genetic Studies (DIGS) was used to obtain socio-demographic and 
clinical information for diagnostic formulation of all study participants including the proband, 
their non-psychiatric first degree relatives, and unrelated non-psychiatric controls (Nurnberger et 
al., 1994).  The Diagnostic Interview for Genetic Studies (DIGS) developed by the NIMH is a 
semi-structured interview for (poly-) diagnostic formulation using standard diagnostic criteria 
(Nurnberger et al., 1994).  Sections A and B capture demographic information and medical 
history respectively.  The kappa coefficients for test-retest reliability (4-10 day interval) of the 
scale for depression, bipolar disorder and schizophrenia, is 0.94, 0.96 and 0.75 respectively 
(Nurnberger et al., 1994).   
As per recommendations, the DIGS was administered by staff who were experienced in 
psychiatric interviewing and assessing manifest psychopathology. The broad similarities in the 
inclusion and exclusion criteria of the 4 studies facilitated the pooling of data in order to examine 
4 separate data sets as one single sample.  One of the studies enrolled only African-American 
subjects (1R01MH066263), while another study enrolled only Caucasian subjects 
(1R01MH063480). 
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3.3.3 Case Definition and Study Samples 
Psychiatric diagnosis for case identification was culled from the DIGS for the following DSM-
IV categories for “Schizophrenia and Other Psychotic Disorders (295.xx); 295.30 – Paranoid 
Type, 295.10 – Disorganized Type, 295.20 – Catatonic Type, 295.90 – Undifferentiated Type, 
295.60 – Residual Type, 295.40 – Schizophreniform Disorder, and 295.70 – Schizoaffective 
Disorder.  Other co-morbid Axis 1 diagnoses (for cases of ‘Schizophrenia’ identified above) 
were also extracted from the database.  The diagnosis for each case was confirmed after 
consensus between two psychiatrists.  Family history of psychiatric illness, particularly 
schizophrenia, was ruled out for healthy controls recruited for all studies. 
Two study samples were examined.  The first sample excluded subjects with the 
following Axis 1 psychiatric diagnoses: psychotic disorder NOS, delusional disorder, brief 
psychotic disorder, psychotic disorder due to a medical condition or substance-induced psychotic 
disorder, all dementias (290.xx), dementia due to medical condition and dementia NOS, and 
mental retardation.  The second sample excluded subjects with any Axis I or Axis II disorder.  
The rationale for extracting these two samples was to compare the results of a ‘generalizable’ 
sample (which included subjects with other Axis 1 diagnoses) to a ‘pure’ sample (which 
excluded subjects with any Axis 1 or 2 disorder).  All analyses were carried out for both samples.  
Differences in results obtained for the two samples, if any, are highlighted. 
3.3.4 Data Extraction 
Prior to analysis, distribution of the variables was examined and data transformations completed 
to reduce skewness.  Other data reduction techniques including recoding and stratification were 
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also carried out. Diabetes and hypertension were recorded on the DIGS in a text field.  These 
variables were extracted from text fields, coded, and added to the database.  These disorders 
were recorded in response to Item B1 in Section B. Medical History: Have you ever had any 
serious physical illness or medical problems? Search terms used for diabetes included: diabetes, 
DM, T2DM, type-2 diabetes, sugar diabetes, NIDDM (non-insulin dependent diabetes), 
maturity-onset diabetes, gestational diabetes, DKA or diabetic ketoacidosis, hyperglycemia, pre-
diabetes, or insulin resistance.  Type-1 diabetes was excluded.  Search terms used for 
hypertension included: hypertension, HT, HTN, blood pressure, or high blood pressure. 
3.3.5 Statistical Methods 
The demographic characteristics of the study sample were examined using descriptive statistics 
using one-way ANOVA for continuous variables and n X k tables for categorical variables.  A 
Mantel-Haenszel modified chi-square was also used for comparison of two dichotomous 
categorical variables controlling for a third categorical factor.  Analyses within each study group 
(Patients with schizophrenia, 1st degree relatives and Controls) were carried out using 
multivariate logistic regression with diabetes or hypertension (coded 1=present and 0=absent) as 
the dependent variable and ‘socio-demographic risk factors’ as independent variables.  
Independent variables that were significantly associated with diabetes or hypertension were 
selected for inclusion in the regression model.  These analyses produced a regression coefficient 
(β) for each independent variable, for example P{y=1} = 1/(1+exp(-(β0 + β1.Age + β2.Gender + 
β3.Race + β4.Years of Schooling.... + βk*Xk)), the exponential conversion of which yielded an 
odds ratio.  A 95% confidence interval for each Odds Ratio was also obtained.  The calibration 
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of the multivariate logistic regression model was examined using the Hosmer-Lemeshow test for 
goodness of fit. 
In order to examine the differential effect(s) that risk factors may have in various study 
groups, another set of multivariate logistic regression using diabetes or hypertension as the 
dependent variable and ‘socio-demographic risk factor’ and ‘group’ as independent variables 
was performed.  This model allowed the examination of the effect that group membership 
(patients with schizophrenia, 1st degree relatives and controls) may have had on associations with 
diabetes or hypertension along with other socio-demographic factors.  A stepwise regression 
using backward elimination was performed in all cases to find the best fitting model.  All results 
were interpreted with an alpha level set at 0.05. 
3.4 RESULTS 
Although separate analyses were performed for the two study samples (‘generalizable’ sample 
with Axis 1 comorbidities and ‘pure’ sample without Axis 1 or 2 comorbidities) results of only 
the ‘generalizable’ sample are presented.  Results for the two samples were essentially similar 





3.4.1 Socio-Demographic Characteristics     
The socio-demographic characteristics of the study sample are presented in Table 4.   
 







X2 / F p 
AGE (Years) 38.8+10.6 42.9+16.1 43.0+15.6 34.9 < 0.001 
SCHOOLING (Years) 12.5+2.6 12.6+2.7 13.3+2.9 17.1 < 0.001 
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The ‘generalizable’ sample comprised of 1524 subjects with schizophrenia or related 
disorders, 778 1st degree relatives and 527 controls. The following variables were recoded; 
Marital Status – reduced from 5 categories to 3, Living Alone – reduced from 8 categories to 2, 
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and Occupation – reduced from 22 categories to 3.  Categories for these variables were reduced 
to prevent over-fitting the model as there were several subgroups with very few (< 5) or no cases.     
Patients with schizophrenia were significantly younger than their 1st degree relatives and 
controls.  It is important to note that while several 1st degree relatives may have been enrolled in 
the genetic studies, only one unaffected (non-psychiatric) 1st degree relative was chosen for 
inclusion in this study.  The 1st degree relative who was an adult (> 18 years of age) sibling and 
closest in age to the proband (patient with schizophrenia) was preferably chosen.  In the absence 
of an adult sibling, a parent was chosen. 
There was a significant over-representation of African-American subjects especially 
among 1st degree relatives and controls.  This was a result of a larger representation of African-
American subjects from one of the four studies (1R01MH066263 – this enrolled only African-
American subjects with schizophrenia, their 1st degree relatives and healthy controls) from 
which the study sample was derived.  Controls had significantly higher mean years of education 
as compared with patients with schizophrenia and 1st degree relatives, groups that did not differ 
from one another.  Although a significant result for religion was observed, this factor was not 
included in subsequent analyses because 1) there was no theoretical basis in the literature for its 
inclusion as a risk factor for diabetes or hypertension, and 2) there were cells with very small 
numbers that could not be grouped together.  Marital status was also significantly different 
between groups with almost two-thirds of patients who were never married.  Occupational status 
also differed significantly between groups with high employment in the 1st degree and control 
groups and high rates of disability in patients with schizophrenia.  All of these factors with the 
exception of religion were included in multivariate logistic regression models as independent 
variables. 
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3.4.2 Rates of Diabetes and Hypertension 
The rates of diabetes and hypertension in the three study groups are presented in Table 5. 
Table 5. Raw and Age-Adjusted Rates of Diabetes and Hypertension in the Study Sample 
 
Schizophrenia 
n = 1524 
1st Degree 
n = 778 
Controls 
n = 527 
P 
DIABETES Unadjusted (Raw) 10.6% 9.1% 6.5% 0.02 
 Age-Adjusted 11.4% 8.2% 5.5% <0.001 
HYPERTENSION Unadjusted (Raw) 17.8% 8.6% 9.5% < 0.001 
 Age-Adjusted 18.8% 7.6% 8.4% <0.001 
  
There were significant differences in the unadjusted and age-adjusted rates of both 
diabetes and hypertension in the three study groups.  Post-hoc differences in unadjusted rates 
between groups were obtained by comparing the column proportions using Bonferroni procedure 
with an adjusted ‘p’ (significance).  The unadjusted rates of diabetes in patients with 
schizophrenia were significantly (1.6 times) higher than controls.  There were however no 
significant differences between the unadjusted rates for diabetes in patients with schizophrenia 
and their 1st degree relatives.  The unadjusted rates for hypertension were significantly higher in 
patients with schizophrenia compared to their 1st degree relatives (2.1 times) and healthy control 
subjects (1.9 times).  Post-hoc comparisons of age-adjusted rates showed significantly higher 
rates for both diabetes and hypertension in patients with schizophrenia as compared with both 
their first degree relatives and controls.   
As patients with schizophrenia were younger than their first degree relatives and controls, 
age-specific rates of diabetes and hypertension were also examined the three groups.  The results 
are presented in Table 6. 
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n = 1524 
1st Degree 
n = 778 
Controls 
n = 527 
 Diabetes Hypertension Diabetes Hypertension Diabetes Hypertension 
< 20 3.6% 10.7% 0.0% 0.0% 0.0% 3.8% 
21 to 30 3.8% 11.3% 1.4% 2.2% 1.8% 1.8% 
31 to 40 9.3% 13.4% 7.1% 5.0% 3.1% 7.2% 
41 to 50 13.4% 21.3% 8.2% 6.8% 6.5% 7.2% 
51 to 60 20.5% 33.5% 15.7% 13.9% 8.6% 21.0% 
> 60 11.5% 23.1% 21.1% 23.7% 18.1% 18.1% 
 
An incrementally higher rate of diabetes and hypertension was observed for both diabetes 
and hypertension for each higher age strata to the age of 60 years in all three groups.  In the age 
group 60 years and older, the rates of both diabetes and hypertension in patients with 
schizophrenia were lower that the rates in the preceding age group, 51 to 60 years.  Similar 
trends have been reported in other studies and have been attributed to a ‘survivor effect’ where 
only healthy individuals (who are free from disease) may survive (Subramaniam et al., 2003; 
Richardson et al., 2004).  
 Given the over-representation of African-American subjects in the study sample, these 
differences were separately examined in the two racial groups.  The results are presented in 
Table 7. 
Table 7. Rates of Diabetes and Hypertension in Racial Groups 
 Race Schizophrenia 
n = 1524 
1st Degree 
n = 778 
Controls 
n = 527 
Diabetes 
Caucasian 8.3% 5.3% 4.6% 
African-American 13.1% 10.1% 7.0% 
Hypertension 
Caucasian 6.8% 4.6% 5.5% 
African-American 30.8% 9.6% 10.7% 
 
Trends similar to those observed in the combined sample were also observed in the racial 
groups separately.  The rates for diabetes and hypertension were higher among African-
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American subjects compared to Caucasian subjects in all study groups. The rates for both 
diabetes and hypertension were also higher in patients with schizophrenia compared to controls 
of the same race. 
3.4.3 Risk Factors for Diabetes and Hypertension in Study Groups Examined Separately  
Risk factors for diabetes and hypertension were examined in each of the study groups separately.  
The independent variables (risk factors) included in these analyses were age, race, marital status, 
years of schooling, living alone, and occupation.  A summary of these results is presented in 
Table 8. 
Table 8.  Risk Factors for Diabetes in Study Groups Separately 
STUDY GROUP Schizophrenia 1st Degree Relatives Controls 
Risk factors 
(Independent Variables) 
(B) p OR / 
Exp (B) 
(B) p OR / 
Exp (B) 
(B) p OR / 
Exp (B) 
Age (years) <0.001 1.05* < 0.001 1.06 0.001 1.06* 
Race (RC = Caucasian) 0.004 1.69* 0.029 2.55 0.103 2.56 
Sex (RC = Male) 0.29 1.13 0.39 0.76 0.39 0.86 
Marital Status (RC = Married) 0.86  0.64  0.31  
Years of Schooling 0.65 0.98 0.46 1.04 0.91 1.04 
Living Alone (RC = Alone) 0.92 0.98 0.78 0.91 0.57 1.49 
Occupation (RC = Employed) 0.21  0.11  0.029  
Disabled  1.14  2.19 0.008 1.47* 
RC = Reference Category 
(B) p = Significance for the regression coefficient associated with the independent variable 
OR / Exp (B) = Odds Ratio derived from exponentiation of the regression coefficient.  
* = Odds Ratios that did not include the null value (‘1’) . 
 
In patients with schizophrenia, (increasing) age and (African-American) race were 
significant risk factors for diabetes.  This model also included sex, marital status, years of 
schooling, living status (living alone) and occupation.  A stepwise regression using backward 
elimination also confirmed that age and race were the two best risk factors for diabetes.  Similar 
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results were found in the group of 1st degree relatives.  In the control group however, age but not 
race was a significant risk factor.  In addition, occupational status, particularly disability 
(category = being disabled) was also a significant risk factor of diabetes.  Stepwise regression 
with backward elimination confirmed the significance of these risk factors in all cases. 
 The adjusted odds ratios derived from exponentiation of the regression coefficient, for 
age for all three study groups, for race, for patients with schizophrenia and their 1st degree 
relatives, and for disability in controls are also presented in Table 4.  The corresponding 95th 
percent confidence intervals for these odds ratios did not include ‘1’.  In patients with 
schizophrenia and their 1st degree relatives, age and race were significant risk factors for 
diabetes.  However, in controls, age and being disabled were significant risk factors of diabetes.  
Race was not a significant risk factor of diabetes for controls.  
 The risk factors for hypertension in the three study groups are presented in Table 9.    
Table 9. Risk Factors for Hypertension in Study Groups Separately 
 Schizophrenia 1st Degree Relatives Controls 
Risk factors 
(Independent Variables) 
(B) p OR / 
Exp (B) 
(B) p OR / 
Exp (B) 
(B) p OR / 
Exp (B) 
Age (years) < 0.001 1.04* < 0.001 1.06* 0.001 1.05* 
Race (RC = Caucasian) < 0.001 6.67* 0.003 4.20* 0.005 4.13* 
Sex (RC = Male) 0.16 0.8 0.28 1.4 0.07 1.88 
Marital Status (RC = Married) 0.46  0.50  0.64  
Years of Schooling 0.61 1.02 0.12 1.08 0.15 1.08 
Living Alone (RC = Alone) 0.13 0.79 0.39 1.42 0.63 0.82 
Occupation (RC = Employed) 0.34  0.62  0.59  
RC = Reference Category. 
(B) p = Significance for the regression coefficient associated with the independent variable 
OR / Exp (B) = Odds Ratio derived from exponentiation of the regression coefficient. 
*= Odds Ratios that did not include the null value (‘1’). 
 
Similar to the results for diabetes, (increasing) age and (African-American) race were 
significant risk factors for hypertension in patients with schizophrenia, their 1st degree relatives 
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and controls.  This model also included sex, marital status, years of schooling, living status 
(living alone) and occupation.  In these analyses, stepwise regression with backward elimination 
confirmed the significance of these risk factors in all groups. 
The adjusted odds ratios for age and race for all three groups are presented in Table 5.  In 
patients with schizophrenia, African-American race (in comparison to Caucasian) was associated 
with a 6.7 times higher likelihood of having hypertension, controlling for age, marital status, 
years of schooling, living alone, and marital status. 
3.4.4 Risk Factors for Diabetes and Hypertension in the Combined Sample 
The results of multivariate logistic regressions using group assignments as an additional 
independent variable for associations with diabetes and hypertension are presented in Table 10.  
In these analyses, the study group comprising of patients with schizophrenia was used as the 
reference category. 
Table 10. Risk Factors for Diabetes and Hypertension in Combined Sample 
 Diabetes Hypertension 
Risk factors 
(Independent Variables) 
(B) p OR / 
Exp (B) 
(B) p OR / 
Exp (B) 
Age (years) < 0.001 1.05* < 0.001 1.05* 
Race (RC = Caucasian) < 0.001 1.84* < 0.001 6.11* 
Sex (RC = Male) 0.80 1.04 0.95 0.99 
Marital Status (RC = Married) 0.43  0.20  
Years of Schooling  0.83 1.01 0.09 1.04 
Living Alone (RC = Alone) 0.90 1.02 0.86 0.86 
Occupation (RC = Employed) 0.024  0.12  
Disabled 0.015 1.6* 0.056 1.40 
Study Group (RC = Patients with Schizophrenia) < 0.001  < 0.001  
1st Degree Relatives 0.003 0.55* < 0.001 0.20* 
Controls <0.001 0.41* < 0.001 0.23* 
RC = Reference Category. 
(B) p = Significance for the regression coefficient associated with the independent variable 
OR / Exp (B) = Odds Ratio, *= Odds Ratios that did not include the null value (‘1’). 
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In these models, (increasing) age and (African-American) race were significant risk 
factors for both diabetes and hypertension.  Occupation (category = being disabled) was a 
significant risk factor for diabetes but not for hypertension.  Both models also showed that the 
risk for both diabetes and hypertension was lower among 1st degree relatives, and in controls 
compared to the risk in patients with schizophrenia.  The corresponding 95th percent confidence 
intervals of the odds ratios for any of the significant risk factors did not include ‘1’. 
The analyses using the smaller (‘pure’) sample in which all co-morbid Axis 1 and Axis 2 
disorders were excluded yielded essentially similar results to that obtained in the inclusive 
(‘generalizable’) sample.   Magnitudes of the significant associations in the ‘pure’ sample were 
either smaller in size, or were reduced to trends (p = 0.05 thru 0.1) but were in the predicted 
directions to the associations observed in the ‘generalizable’ sample.  Given the similarities in 
findings between the two samples, the results for the ‘pure’ sample have not been presented. 
3.5 DISCUSSION 
This study compared the rates for diabetes and hypertension, and provided a comprehensive 
assessment of associated socio-demographic risk factors, in patients with schizophrenia, their 1st 
degree relatives, and contemporaneously enrolled healthy controls.  The age-adjusted rates for 
diabetes and hypertension in patients with schizophrenia (11.4% and 18.8% respectively) were 
higher than the rates observed in healthy control subjects (5.5% and 8.4% respectively). 
Although higher rates for diabetes and hypertension in patients with schizophrenia have been 
reported previously, wide variations in study population, sampling techniques and study 
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design/methodology and diagnostic criteria used have produced varying estimates for both 
disorders. Furthermore, methods for ascertaining diabetes also have varied and have ranged from 
conducting glucose tolerance tests in prospective studies, to enumeration of recorded diagnoses 
in insurance and administrative databases in retrospective studies.  These factors make 
comparison of prevalence rates across studies challenging, and emphasize the need to only 
compare studies that share critical characteristics. 
The observed rates for both diabetes and hypertension are lower in comparison to studies 
that are similar in scope and have included a comparison group.  Nasrallah and colleagues (2006) 
observed diabetes rates of 14% and 7% in patients with schizophrenia and controls in contrast to 
11.4% and 5.5% observed in this study.  Similarly, another study showed hypertension rates of 
20% and 15% for patients with schizophrenia and healthy controls in contrast to rates of 18.8% 
and 8.4% respectively, observed in this study (Lumby et al., 2007).  One possible explanation for 
the lower rates observed here may be the effect of condensing data acquired over approximately 
20 years into a single cross-sectional estimate.  Therefore, the observed estimates in this study 
may not accurately reflect the point prevalence for diabetes and hypertension.  Despite this 
limitation, comparisons of rates across contemporaneously enrolled groups of 1st degree relatives 
and controls within the same time-frame remain valid. 
Age was a significant risk factor for diabetes and hypertension.  It is a known risk factor 
for these two disorders and for cardiovascular diseases in general.  In patients with 
schizophrenia, cross-sectional age-stratified rates for diabetes show a 10-fold increase from 4% 
in patients aged 30-39 years, to 50% in patients aged 50 to 59 years (Subramaniam et al. 2003).  
African-American race was also a significant risk factor for both diabetes and hypertension.  
This is consistent with higher rates for diabetes in African-American patients with schizophrenia 
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reported in both cross-sectional and longitudinal studies (Dixon et al., 2000; Kreyenbuhl et al., 
2006; Lambert et al., 2005; Ramaswamy et al., 2006).  The role of disability as an effect modifier 
for diabetes remains unclear, although it may be speculated that it is a likely consequence of 
diabetes rather than a factor that affords risk. 
Although bivariate analyses showed that rates for diabetes in 1st degree relatives did not 
differ significantly from the rates in patients with schizophrenia, and were numerically higher 
than the rates in controls, these differences were not borne out in multivariate logistic regression 
analyses that included socio-demographic factors and group membership with 1st degree relatives 
as the reference group.  The rates for hypertension in 1st degree relatives were essentially similar 
to the rates in healthy controls and significantly lower than the rates in patients with 
schizophrenia. 
Age-, race-, and sex-stratified rates of hypertension in patients with schizophrenia for 
purposes of comparison are unavailable.  However, the similarities in the results of risk factors 
for diabetes and hypertension confirm the roles of age and race as important factors for both 
disorders.  Interestingly, none of the other risk factors, namely marital status, living arrangement 
and years of schooling, showed associations either with diabetes or hypertension, although each 
factor differed significantly between the study groups. 
A significant strength of the study is the uniformity with which the data were collected, 
fastidious diagnostic case ascertainment, similarities in the inclusion/exclusion criteria for the 
different studies from which the data were pooled, and the size and uniqueness of the study 
sample.  Additionally, confounding that may result from enrollment of non-contemporaneous 
controls or those derived from national epidemiological surveys is minimized.  Unlike several 
studies in the literature, the study sample is heterogeneous with respect to distribution of 
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demographic and social characteristics.  Thus, the external validity (generalizability) of findings 
from such a sample is likely to be high. 
The proposed study also has several weaknesses.  First, no assumptions of causality can 
be made in this cross-sectional study as temporal precedence cannot be established.  Second, the 
characterization of diabetes and hypertension is based only on the subject’s self-report to an 
open-ended question without any additional corroboration.  Studies using this methodology 
usually result in an under-estimate of the outcome (Elliott and Huizinga, 1989).  This may have 
also accounted for the lower than expected rates of diabetes and hypertension.  Third, although 
quite comprehensive in its scope, this study does not address all possible factors and mechanisms 
that may account for the development of medical comorbidities in patients with schizophrenia.  
Chiefly, a measure of body weight (or Body Mass Index (BMI)) is not available and therefore, 
the role of obesity as a risk factor for the development of diabetes and hypertension cannot be 
accounted for.  This limitation is unlikely to affect the validity of the relationship(s) between the 
other proposed risk factors and diabetes and hypertension because as previously stated, the rates 
of obesity are quite high in this population and body weight is only one of many potential factors 
that may lead to the development of diabetes or hypertension.  Furthermore, the range of socio-
demographic variables included in this study is limited and restricted only to the data obtained 
using the DIGS. These limitations notwithstanding, the comparison of various study groups 
continues to have high internal validity because the biases apply to all subjects uniformly. 
Racial disparities in cardiovascular diseases are well-documented (Keppel et al., 2002).  
In addition to a higher genetic predisposition for diabetes and hypertension, socio-economic 
factors and reduced access to care also contribute to disease burden borne by African-American 
patients (Williams et al., 2010).  The Substance and Mental Health Services Administration has 
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recognized the increased mortality resulting from chronic medical illnesses in patients with 
severe mental illnesses and is spearheading the “10 X 10 Wellness Campaign” to increase life 
expectancy by 10 years in 10 years (10 X 10) for people with mental illness.  To that end, this 
study further makes the case for increased attention and resources for adequate treatment and 
ongoing management of diabetes and hypertension in African-American patients with 
schizophrenia. 
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4.0  AN ASSOCIATION OF SMOKING, ALCOHOL, AND MARIJUANA USE WITH 
DIABETES AND HYPERTENSION IN PATIENTS WITH SCHIZOPHRENIA AND 
RELATED DISORDERS 
4.1 ABSTRACT 
Introduction: The rates of smoking, alcohol and marijuana use in patients with schizophrenia are 
higher than in the general population.  The role that these factors play in contributing to poor 
clinical and social outcomes in this population is well documented, but their effects on physical 
health outcomes have not been examined systematically.  Diabetes and hypertension, two 
common prototypical chronic medical conditions that co-occur at high rates in schizophrenia are 
related to premature mortality in patients.  Associations between lifestyle factors and diabetes 
and hypertension, if any, may help to elucidate the effect that these factors have in contributing 
to the increased mortality in this population.  
Methods: A retrospective cross-sectional study with pooled data from four major genetic studies 
was carried out to examine the associations that lifestyle factors, such as smoking, alcohol and 
marijuana use, have with diabetes mellitus and hypertension in patients with schizophrenia, their 
non-psychiatric unaffected 1st degree relatives and unrelated healthy controls.  Data were 
extracted from the Diagnostic Interview for Genetic Studies (DIGS) questionnaire which was 
used for diagnostic formulation of all cases.  Data for diabetes and hypertension were extracted 
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from text fields using a large set of search terms.  Two measures for each lifestyle factor were 
selected, one noting the presence or absence of the factor and the other its severity or duration.  
Contingency statistics were used to compare the rates of smoking, alcohol and marijuana use in 
the study groups.  In the case where these associations were examined while controlling for a 
stratifying variable, a Mantel Haenszel chi-square test was used.  Associations between lifestyle 
risk factors and diabetes or hypertension, controlling for socio-demographic factors, were 
examined using multivariate logistic regression analysis.  Stepwise regression with backward 
elimination was used to find the best fitting model. 
Results: The rates of smoking, alcohol, and marijuana use were significantly higher in patients 
with schizophrenia than the rates in contemporaneously recruited controls.  The rates of smoking 
and marijuana in 1st degree relatives were similar to the rates observed in controls and 
significantly lower than the rates in patients with schizophrenia.  However, the rates of alcohol 
use in 1st degree relatives were higher than in controls and marginally lower than the rates in 
patients.  Although bivariate analyses between lifestyle factors and diabetes or hypertension in 
the pooled sample showed an inverse relationship between marijuana use and diabetes, and a 
direct relationship between smoking and hypertension, unconditional multivariate logistic 
regression analyses that adjusted for socio-demographic factors did not show any association 
between any of the lifestyle factors and diabetes or hypertension.  
Conclusions:  These data support the high rates of smoking, alcohol and marijuana use observed 
in patients with schizophrenia.  First degree relatives of patients with schizophrenia did not differ 
from controls in smoking and marijuana use. The rates of alcohol use in 1st degree relatives were 
higher than in controls.  Multivariate analyses that controlled for socio-demographic factors did 
not show any associations between smoking, alcohol or marijuana use, and diabetes or 
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hypertension.  However, future studies must re-examine these relationships by including 
important factors such as family history of diabetes or hypertension, a measure of adiposity, and 
lifetime use of obesogenic and diabetogenic psychotropic medications.  
Public Health Significance: High rates of substance abuse in patients with schizophrenia 
contribute to poor behavioral and physical outcomes, and underscore the need for primary and 
secondary prevention measures in order to reduce premature mortality in this population. 
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4.2 INTRODUCTION 
Lifestyle factors such as poor diet and nutrition, physical inactivity, and smoking contribute to 
the increased mortality observed in patients with schizophrenia (Brown, 1997; Brown et al., 
1999; Brown et al., 2000).  Despite the high rates of these lifestyle factors, the morbidity and 
mortality associated with other lifestyle factors such as alcohol and marijuana use in patients 
with schizophrenia have not been systematically examined (Regier et al., 1990).  In the absence 
of longitudinal data, a cross-sectional association between these common lifestyle factors and 
chronic medical illnesses such as diabetes mellitus and hypertension may shed some light on the 
role that these risk factors might have on the premature mortality in this population.     
 The rationale for selecting diabetes mellitus (herein referred to as diabetes) and 
hypertension has been discussed in an earlier study (Brar, Paper 2).  In that study, higher rates of 
diabetes and hypertension were observed in patients with schizophrenia compared to healthy 
controls, and the rates of both disorders increased with age and African-American race (Brar, 
Paper 2).  If preliminary associations between common lifestyle factors such as smoking, 
alcohol, and marijuana use with diabetes or hypertension are observed, and a cause-and-effect 
relationship is borne out by longitudinal studies, the need to develop specialized services to 
address these modifiable risk factors will take on renewed importance. 
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4.2.1 Smoking in Schizophrenia 
The rates of smoking in patients with schizophrenia range from 58% to 90%, rates that are 2 to 3 
times higher than those observed in the general population (Moeller-Saxone, 2008; Chaves and 
Shirakawa, 2008).  Furthermore, patients with schizophrenia also tend to be heavy smokers 
drawing higher levels of nicotine from cigarettes (de Leon et al., 1995).  These high rates result 
from several psychological, behavioral and environmental causes that make smoking cessation a 
challenging endeavor in this population (William and Foulds, 2007; Fagerstrom and Aubin, 
2009).  Cigarette smoking in patients has been linked with higher than expected rates of chronic 
obstructive pulmonary disease and other respiratory and heart diseases ( Oud and Meyboom-de 
Jong, 2009).  
4.2.2 Association of Smoking with Diabetes or Hypertension 
Smoking has been listed along with diabetes and hypertension as an important risk factor for 
cardiovascular disease (Wilson, 2010).  However, a recent meta-analysis has shown that smoking 
is in fact an independent risk factor for the development of diabetes mellitus (Willi et al., 2009).  
Smoking has been shown to affect beta cell functions and cause insulin resistance thereby 
increasing the risk for the development of diabetes (Facchini et al., 1992; Attvall et al. 1993). 
Smoking has also been linked to incident hypertension and decreased regional left ventricular 
function (Rosen et al., 2006; Bowman et al., 2007). 
A clustering of smoking, diabetes, hypertension and other lifestyle risk factors has been 
reported to explain premature mortality in patients with schizophrenia (Connolly and Kelly, 
2005).  A recent review and an accompanying editorial have also suggested an independent role 
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of smoking for the increased prevalence of diabetes and hypertension, but this has not been 
empirically investigated (Wildgust et al., 2010; Wildgust and Beary, 2010).   
4.2.3 Alcohol Use in Schizophrenia 
Alcohol is the second commonest substance abused by patients with schizophrenia after smoking 
(Batel, 1995).  Although a third of patients with schizophrenia meet diagnostic criteria for an 
alcohol use disorder (AUD), the number of patients who drink is considerably higher (Regier et 
al., 1990).  Similar to smoking, alcohol use in schizophrenia is also associated with 
psychological, behavioral and environmental causes (Drake and Meuser, 2002), and is associated 
with medication non-compliance, frequent hospitalization, risk of violence, and poor overall 
health and functioning in patients with schizophrenia (Drake et al., 1989).    
4.2.4 Association of Alcohol Use with Diabetes or Hypertension 
While moderate drinking is associated with a lower risk of diabetes (Kopper et al., 2005), heavy 
drinking can lead to obesity and insulin resistance (Shah et al., 1988).  A recent meta-analysis 
has shown that abstainers and heavy alcohol drinkers had a higher risk for developing diabetes in 
comparison to moderate drinkers (Baliunas et al., 2009).  This U-shaped relationship was true for 
both men and women (Baliunas et al., 2009).   Moderate drinking exerts a protective effect for 
the development of diabetes by improving insulin sensitivity (Kiechl et al., 1996).  Alcohol 
consumption also has a J-shaped association with cardiovascular disease outcomes including 
mortality (Costanzo et al., 2010).   Similar to diabetes, moderate alcohol consumption may also 
have a beneficial effect on blood pressure (Xin et al., 2001).   This may result from vasodilation, 
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an acute effect of alcohol consumption.  On the other hand, regular drinking over a prolonged 
period of time may have a linear effect on blood pressure increasing the incidence of 
hypertension (Puddey et al., 1985; Puddey and Beilin, 2006).  Furthermore, the risk of 
hypertension increases when alcohol is consumed in the absence of food (Stranges et al., 2004). 
The associations between alcohol use and diabetes or hypertension have not been 
examined in patients with schizophrenia.  However, it can be speculated that the risk for both 
disorders in patients who consume alcohol may be high because of heavy drinking and poor 
dietary habits observed in this population (Drake et al., 1990; Peet, 2004). 
4.2.5 Marijuana Use in Schizophrenia 
Marijuana use has been shown to increase the risk for developing schizophrenia (Kuepper et al., 
2011).  After smoking and alcohol, it is the next most common substance for abuse in patients 
with schizophrenia (Reiger et al., 1990).  Prevalence rates for marijuana use vary considerably 
by sample composition, recruitment source, method for diagnosis and data collection (Green et 
al., 2005).  A review of cannabis use and misuse studies estimated the lifetime prevalence rates 
in patients with schizophrenia to be 42.1% and 22%, respectively (Green et al., 2005).  Another 
cohort study estimated the lifetime cannabis use to be 66.2% (Foti et al., 2010).  This study also 
showed that ongoing cannabis use was associated with a worse outcome with respect to positive 
(psychotic) symptoms in patients with schizophrenia (Foti et al., 2010). 
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4.2.6 Association of Marijuana Use with Diabetes or Hypertension 
A recently published study has shown that the prevalence of diabetes was lower among 
marijuana users compared to non-users (Rajavashisth et al., 2012).  The authors examined data 
from 10,896 adults who participated in the third National Health and Nutrition Examination 
Survey (NHANES-III, 1988 – 1994) and found that marijuana users had a lower age-adjusted 
prevalence of diabetes compared to non-users (Odds Ratio = 0.42, 95th % confidence interval = 
0.33 – 0.55).  The authors of this study postulated that the decreased prevalence diabetes was 
possibly related to the anti-inflammatory and antioxidant effect of bioactive cannabinoids in 
marijuana.  The only other published study that has examined the association between marijuana 
use and diabetes found similar glucose levels in users and non-users (Rodondi et al., 2006).  
Short-term effects of marijuana on the cardiovascular system include tachycardia, spike in blood 
pressure, and orthostatic hypotension, but the effects on blood pressure are attenuated with long-
term use (Sidney, 2002; Frishman et al., 2003).  Heavy marijuana use may trigger the onset of 
myocardial infarction and increase the risk for stroke (Sidney, 2002; Frishman et al., 2003). The 
study by Rajavashisth and colleagues (2012) did not find an association between marijuana use 
and hypertension. 
A systematic review that was conducted as part of this dissertation showed that there 
were either too few or no studies that examined the roles of lifestyle factors, namely smoking, 




This study examined the associations between lifestyle risk factors of smoking, alcohol and 
marijuana use and diabetes and hypertension in patients with schizophrenia, their unaffected 
(non-psychiatric) first-degree relatives (including siblings and parents), and contemporaneously 
enrolled unrelated and unaffected controls.  The confounding effects that socio-demographic 
factors such as age, race, sex and years of schooling may have on the associations between 
lifestyle factors and diabetes and hypertension are also examined.  It is hypothesized that 
lifestyle factors will show associations with diabetes and hypertension similar to that observed in 
the general population.  Furthermore, the associations between lifestyle risk factors and diabetes 
and hypertension are likely to be strongest in patients with schizophrenia as the prevalence of 
these factors is expected to be higher in that group.   
4.3 METHODS 
4.3.1 Data for the Study 
Data extraction procedures for this study have been described previously (Brar, Paper 2). Briefly, 
data pooled from four large NIMH-funded studies investigating the genetic basis for 
schizophrenia were analyzed.  Three study groups were assembled: patients with schizophrenia 
and related disorders (probands), their non-psychiatric first degree relatives, and unrelated non-
psychiatric controls who were recruited from the same geographic area as the patients. 
 93 
4.3.2 Diagnostic Interview for Genetic Studies 
The Diagnostic Interview for Genetic Studies (DIGS) was used to obtain socio-demographic and 
clinical information for diagnostic formulation of all study participants including the proband, 
their non-psychiatric first degree relatives, and unrelated non-psychiatric controls (Nurnberger et 
al., 1994).  This instrument has a high test-retest reliability for schizophrenia (Nurnberger et al., 
1994).  Procedures for the extraction of socio-demographic and medical variables (diagnosis of 
diabetes and hypertension) used for this study have been described previously (Brar, Paper 2). 
4.3.3 Extraction of Data Related to Lifestyle Factors 
Data for smoking, alcohol use and marijuana use were extracted from sections ‘A. 
Demographics’, ‘I. Alcohol Abuse and Dependence’ and ‘J. Drug Abuse and Dependence’, 
respectively.  For each lifestyle factor, two variables were selected.  The first variable selected 
most closely approximated lifetime use of the lifestyle factor, the second represented its severity.  
In the absence of a good measure of severity, lifetime duration of use was chosen as a surrogate 
marker. 
Smoking-related information is recorded in section ‘A. Demographics’ of the DIGS.  
Each subject is asked 3 questions; 1) had the subject ever smoked cigarettes (recorded as ‘No’, 
‘Yes, Currently’, and ‘Yes, In the Past’, 2) number of packs smoked per day and, 3) number of 
years smoked.  A severity measure of ‘Pack-Years’ is then calculated as the product of ‘packs 
smoked per day’ and ‘number of years smoked’.  For the first measure (had the subject ever 
smoked cigarettes), the three categories were reduced to a dichotomous response (Yes or No) by 
combining ‘Yes, Currently’ and ‘Yes, In the Past’.  The categories were collapsed because 1) 
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both smoking currently or in the past was likely to have exerted similar effects on the 
development of chronic medical conditions such as diabetes or hypertension and 2) to align this 
variable with similar variables obtained from alcohol and marijuana use representing lifetime 
use.  ‘Pack-Years’ was selected as the measure of severity of smoking, in addition to the 
dichotomous variable. 
Alcohol use-related information was extracted from two questions in section ‘I. Alcohol 
Abuse and Dependence’.  Question 5 in this section inquired whether the subject ever drank 
regularly (at least once a week for six months or more) – with a dichotomous response of Yes or 
No.  If the response to this question was ‘Yes’, the next question asked the age at which the 
subject started to drink regularly.  Age of onset of regular drinking was selected as a measure of 
severity for alcohol use.      
Marijuana use-related information was extracted from two questions in the ‘Marijuana’ 
section in ‘J. Drug Abuse and Dependence’.  Question 1 inquired whether the subject ever used 
marijuana – with a dichotomous response of Yes or No.  The marijuana section of the DIGS 
further elicits the duration of marijuana use that is accompanied by contemporaneous 
experiences involving any two of the following; preoccupation with obtaining marijuana, a broad 
range of psychological problems relating to marijuana use, feeling jumpy, startled or nervous, 
inability to cut down use of marijuana, gradually requiring larger quantities of marijuana, 
experiencing co-occurring physical symptoms (such as insomnia, nervousness, sweating, nausea 
or diarrhea), putting oneself in situations that could cause harm after using marijuana, family and 
friends objecting to marijuana use, reduced family and social interactions, under the influence of 
marijuana at school or work, or legal problems related to marijuana.  The number of years that 
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the subject had any two these experiences at the same time is calculated and recorded on the 
DIGS.  This variable was used as a surrogate marker for severity. 
It is important to note that probands, i.e. patients with schizophrenia, who had a 
concurrent diagnosis of alcohol or substance abuse and/or dependence were not enrolled in the 
genetic studies.  Similarly, unrelated non-psychiatric controls who also had a concurrent 
diagnosis of alcohol or substance abuse and/or dependence were not enrolled.  However, these 
exclusionary criteria did not apply to 1st degree relatives of patients with schizophrenia.  
4.3.4 Case Definition and Study Samples 
Case definition and assembly of the study sample have been described previously (Brar, Paper 
2).  The group of patients with schizophrenia and related disorders consisted of subjects who met 
DSM-IV diagnostic criteria for any of the schizophrenia subtypes, schizophreniform disorder or 
schizoaffective disorder. Subjects with an Axis 1 diagnosis of psychotic disorder, NOS, 
delusional disorder, brief psychotic disorder, psychotic disorder due to a medical condition or 
substance-induced psychotic disorder, all dementias (290.xx), dementia due to medical condition 
and dementia NOS, and mental retardation were excluded from the sample.  The diagnosis for 
each case was confirmed only after there was consensus between two psychiatrists.  Family 
history of psychiatric illness, particularly schizophrenia and related disorders, was ruled out for 
healthy controls recruited for the genetic studies. 
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4.3.5 Data Extraction 
Data reduction techniques including recoding and stratification of variables and extraction of 
medical information relating to a diagnosis of diabetes and hypertension have been described 
previously (Brar, Paper 2).   
4.3.6 Statistical Methods 
Descriptive statistics were used to examine the demographic characteristics of the study sample.  
These included one-way analysis of variance (ANOVA) for continuous variables and n X k 
tables for categorical variables.  Contingency statistics (2 X 3 tables using crosstab) were used to 
examine differences in the rates of lifestyle factors between study groups.  Differences in the 
severity measures of lifestyle factors were compared using an F-test of a one-way ANOVA. The 
associations between lifestyle factors and diabetes or hypertension were examined using odds 
ratios and their corresponding 95th percent Confidence Interval.  In order to examine the 
association between lifestyle factors and diabetes or hypertension in the pooled sample, a 
Mantel-Haenszel Chi-Square test was used.  This test is applicable for stratified categorical data 
and allows for the comparison of two groups (categorical variables) while controlling for a third 
categorical variable (Mantel and Haenszel, 1959).  The association between lifestyle factors and 
diabetes or hypertension was examined after controlling for study group membership.         
Multivariate logistic regression was used to examine the associations of lifestyle and 
socio-demographic factors with diabetes or hypertension. Diabetes or hypertension (coded 
1=present and 0=absent, the dependent variable) was regressed using both categorical and 
continuous lifestyle and socio-demographic factors.  An odds ratio for each independent factor 
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was obtained by the exponential conversion of its regression coefficient (β).  A corresponding 
95% Confidence Interval for each Odds Ratio was also obtained.  The calibration of the 
multivariate logistic regression model was examined using the Hosmer-Lemeshow test for 
Goodness of Fit.  A stepwise regression using backward elimination of the multivariate logistic 
model was carried out to determine the model with the highest association.  All results were 
interpreted with an alpha level set at 0.05. 
The following reference categories were used for the discrete variables in the multivariate 
models; Caucasian for Race, male for Sex, and patients with schizophrenia for study group 
membership.   
4.4 RESULTS 
4.4.1 Socio-Demographic Characteristics     
The socio-demographic characteristics of the study sample are presented in Table 11.  The 
sample consisted of 1524 subjects with schizophrenia or related disorders, 778 1st degree 







Table 11. Description of the Study Sample (Mean + SD or percentage) 
 
There were significant differences in the socio-demographic characteristics in the study 
groups.  Patients with schizophrenia were significantly younger than their 1st degree relatives and 
controls.  A large proportion of 1st degree relatives and controls included in the study sample 
were recruited for a study that enrolled African-American subjects only (R01MH066263).  This 
resulted in a significant over-representation of African-American subjects among 1st degree 
relatives and controls than would be expected from a random sampling of the population. The 
proportion of females among 1st degree relatives and controls was also significantly higher than 
the proportion of females among patients with schizophrenia. Controls in the sample also had 
significantly higher mean years of schooling compared with patients with schizophrenia and 1st 
degree relatives.  The latter two groups did not differ in mean years of schooling from one 
another. 
4.4.2 Rates of Diabetes and Hypertension 
The rates of diabetes and hypertension in the study sample have been described previously (Brar, 







X2 / F p 
AGE (Years) 38.8+10.6 42.9+16.1 43.0+15.6 34.9 < 0.001 
SCHOOLING (Years) 12.5+2.6 12.6+2.7 13.3+2.9 17.1 < 0.001 
























114.7 < 0.001 
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control subjects but not their 1st degree relatives.  The rates of hypertension in patients with 
schizophrenia were higher than both their 1st degree relatives and controls.  These differences 
persisted when examined separately in Caucasian and African-American subjects (Brar, Paper 
2). 
4.4.3 Smoking, Alcohol, and Marijuana Use  
The rate and severity or duration of each lifestyle factor was examined separately in the three 
study groups.  Results are presented in Tables 12. 
Table 12. Rates of Smoking, Alcohol, and Marijuana Use 
Lifestyle Factors  Schizophrenia 
n = 1524 
1st Degree 
Relatives 
n = 778 
Controls 




Smoking Yes 1007 (68.9%) 398 (53.9%) 252 (48.3%) 89.4 < 0.001 
No 455 (31.1%) 341 (46.1%) 270 (51.7%) 
Alcohol Use Yes 702 (51.7%) 324 (46.6%) 192 (38.3%) 26.8 < 0.001 
No 655 (48.3%) 371 (53.4%) 309 (61.7%) 
Marijuana Use Yes 998 (68.5%) 432 (58.1%) 288 (54.8%) 41.8 < 0.001 
No 459 (31.5%) 311 (41.9%) 238 (45.2%) 
 
The sample sizes for the analyses of associations between diabetes and hypertension with 
smoking, alcohol and marijuana use differ, and are smaller than the complete sample because of 
missing data for lifestyle factors.  An examination of missing data prior to the analyses revealed 
that the data were missing at random. 
The rates of smoking in patients with schizophrenia (68.9%) were significantly higher 
than the rates in 1st degree relatives (53.9%) and controls (48.3%).  The rates in 1st degree 
relatives and controls did not differ significantly from one another.  The rates of alcohol use in 
patients with schizophrenia (51.7%) and their 1st degree relatives (46.6%) were significant higher 
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than the rates in controls (38.3%) but did not differ significant from one another.  The rates of 
marijuana use in patients with schizophrenia (68.5%) were also significantly higher than both the 
rates in their 1st degree relatives (58.1%) and controls (54.8%).  There were no statistically 
significant differences in the rates of marijuana use between 1st degree relatives and controls. 
Differences in the severity or duration of smoking, alcohol and marijuana use are 
presented in Table 13. 




n = 1524 
1st Degree 
Relatives 
n = 778 
Controls 




Smoking Pack-Years1 19.2 + 22.2 16.2 + 37.2 14.9 + 18.1 6.2 0.002 
Alcohol Use AOO2 19.03 + 5.3 21.8 + 7.5 21.01 + 5.6 23.4 < 0.001 
Marijuana Use Duration3 6.4 + 7.4 5.6 + 7.9 7.4 + 9.2 0.49 ns 
Pack-Years = packs per day X years smoked 
AOO = Age of Onset, age at which subject started drinking regularly 
Duration in years = Use accompanied by 2 symptoms of disturbance repeatedly for at least 1 
month 
 
The severity of smoking measured by mean ‘Pack-Years’ was significantly higher in 
patients with schizophrenia compared with both their 1st degree relatives and controls.  Similarly, 
the mean age at which patients with schizophrenia started drinking alcohol regularly was lower 
than that in 1st degree relatives and controls.  The latter two groups did not differ from one 
another.  No differences in the severity of marijuana use were observed between the study 
groups.  Both variables, one determining rate of each lifestyle factor (Categorical, in Table 2), 
and the other measuring the severity/duration of the lifestyle factor (Continuous, in Table 3) 
were included in multivariate analyses to examine risk factors for diabetes or hypertension.     
The associations of lifestyle factors with diabetes were examined separately within each 
group and across groups.  The results are presented in Table 14. 
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Table 14. Associations (Odds Ratios and 95th% CI) Between Lifestyle Factors and Diabetes 
 Schizophrenia 
n = 1524 
1st Degree 
Relatives 
n = 778 
Controls 




(0.64 – 1.29) 
1.19 
(0.73 – 1.95) 
1.08 
(0.54 – 2.16) 
1.01 
(0.77 – 1.31) 
Alcohol Use 1.3 
(0.92 – 1.83) 
0.88 
(0.52 – 1.48) 
0.52 
(0.23 – 1.17) 
1.04 
(0.80 – 1.36) 
Marijuana Use 0.73 
(0.52 – 1.03) 
0.67 
(0.41 – 1.11) 
0.59 
(0.29 – 1.20) 
0.69*                     
(0.53 – 0.90) 
*= 95th percent Confidence Intervals for the Odds Ratios that do not include null value (1).   
 
Smoking and alcohol use were not associated with diabetes in any of the study groups 
examined separately or in the pooled sample controlling for study group membership.  Marijuana 
use was not associated with diabetes when examined in the study groups separately but an 
inverse (protective effect) association was observed in the pooled sample that controlled for 
study group membership.  There was a 0.69 times lower likelihood of having diabetes in subjects 
who used marijuana in the study sample after controlling for study group membership (Mantel-
Haenszel X2 = 7.2 (1df), p = 0.007). 
The associations of lifestyle factors with hypertension were examined separately within 
each group and across groups.  The results are presented in Table 15. 
Table 15. Associations (ORs and 95th% CI) Between Lifestyle Factors and Hypertension 
 Schizophrenia 
n = 1524 
1st Degree 
Relatives 
n = 778 
Controls 
n = 527 
Pooled; Mantel-
Haenszel Test 
Smoking 1.38*            
(1.02 – 1.87) 
1.03 
(0.62 – 1.71) 
1.29 
(0.72 – 2.31) 
1.29*               
(1.01 – 1.63) 
Alcohol Use 1.12 
(0.85 – 1.48) 
0.87 
(0.52 – 1.48) 
1.46 
(0.79 – 2.70) 
1.11 
(0.88 – 1.39) 
Marijuana Use 1.29 
(0.96 – 1.74) 
0.29*              
(0.17 – 0.50) 
0.62 
(0.35 – 1.12) 
0.85 
(0.67 - 1.06) 
* = 95th percent Confidence Intervals for the Odds Ratios that do not include null value (1).   
 
 102 
Smoking was associated with a higher likelihood of hypertension (OR = 1.38) in patients 
with schizophrenia but not in 1st degree relatives and controls.  The pooled sample that controlled 
for study group membership also showed a similar significant association between smoking and 
hypertension (Mantel-Haenszel X2 (1df) = 4.02, p = 0.045).  Alcohol use was not associated with 
hypertension in any of the study groups separately or in the pooled study sample.  Marijuana use 
was not associated with hypertension in patients with schizophrenia or controls but an inverse 
association was observed in 1st degree relatives.  However, there was no association in the 
pooled sample controlling for study group membership (Mantel-Haenszel X2 (1df) = 1.86, p = 
ns). 
4.4.4 Lifestyle Factors Associated with Diabetes and Hypertension       
In order to examine the associations between lifestyle factors and diabetes and hypertension after 
controlling for the effect(s) of socio-demographic factors, bi-variate analyses were performed to 
select factors (independent variables) that should be included in multivariate models (data not 
shown).  Socio-demographic factors which were significantly associated with smoking included 
race (both Caucasian and African-American in different groups), male sex, age (↑), and years of 
schooling (↓).  All socio-demographic factors also showed similar associations with alcohol and 
marijuana use, and were included in multivariate analyses examining risk factors for diabetes and 
hypertension.  
Lifestyle factors associated with diabetes or hypertension were examined in each of the 
study groups separately and in the combined sample.  The independent factors included all socio-
demographic variables and the categorical (Yes/No) or continuous (severity or duration) variable 
related to each lifestyle factor.  Data for severity or duration of each lifestyle factor were only 
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available for subjects who were coded as ‘Yes’ for the lifestyle factor.  For example, ‘Pack-
Years’ was relevant only for subjects who had a history of smoking (coded ‘Yes’) and not for 
non-smokers (coded ‘No’).  Because of this multicollinearity between the categorical and 
continuous variables for each lifestyle factor, only one variable (either the categorical or the 
continuous) was used in each multivariate model.  Analysis for the combined sample included 
study group (membership) as an independent factor. 
Results of multivariate analyses examining the association for smoking, alcohol use and 
marijuana use with diabetes are presented in Table 16. 
Table 16. Socio-Demographic and Lifestyle Factors Associated with Diabetes 
 Smoking Alcohol Use Marijuana Use 
Independent Risk 
factors 
(B) p OR / 
Exp (B) 
(B) p OR / 
Exp (B) 
(B) p OR / 
Exp (B) 
Age (years) < 0.001 1.06* < 0.001 1.06* < 0.001 1.06* 
Race (RC = Caucasian) < 0.001 2.01* < 0.001 2.03* < 0.001 1.99* 
Sex (RC = Male) 0.88 1.02 0.68 1.06 0.87 1.03 
Years of Schooling 0.83 1.01 0.84 1.01 0.38 1.01 
Lifestyle Factor 
(Categorical, RC = No) 
0.57 0.92 0.58 1.08 0.38 0.88 
Study Group (RC = 
Schizophrenia) 
< 0.001  < 0.001  < 0.001  
1st Degree Relatives < 0.001 0.46* < 0.001 0.45* < 0.001 0.46* 
Controls < 0.001 0.30* < 0.001 0.32* < 0.001 0.30* 
RC = Reference Category 
(B) p = Significance for the regression coefficient associated with the independent variable 
OR / Exp (B) = Odds Ratio derived from exponentiation of the regression coefficient.  
*=Odds Ratios that do not include the null value (‘1’). 
 
Age, race and study group membership were significant risk factors for diabetes in 
separate analyses for smoking, alcohol use and marijuana use.  Patients with schizophrenia were 
assigned as the reference category for study group membership.  Diabetes was associated with 
increasing age, African-American race and diagnosis of schizophrenia but not with sex, years of 
schooling or the presence of any of the factors.  First degree relatives and controls had a lower 
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likelihood of having diabetes compared to patients with schizophrenia. The 95th percent 
Confidence Intervals for the corresponding odds ratio did not include the null value, 1.  A 
stepwise regression with backwards elimination also confirmed that age, race and study group 
membership were the best risk factors for diabetes.  Separate analyses within each study group 
also confirmed the significant associations between age and race with diabetes (data not shown).  
None of the lifestyle factors had any association with diabetes.  
Multivariate analyses using severity and duration based measures of smoking, alcohol 
and marijuana use showed essentially similar results, but was restricted to the sample that 
included only those subjects in whom the lifestyle factor was present (data not shown).  An 
additional multivariate analysis using all three lifestyle factors simultaneously along with socio-
demographic factors also showed associations for age, race and study group membership only 
(data not shown).  Results of multivariate analyses examining the associations for smoking, 
alcohol use and marijuana use with hypertension are presented in Table 17. 
Table 17. Socio-Demographic and Lifestyle Factors Associated with Hypertension 
 Smoking Alcohol Use Marijuana Use 
Independent Risk 
factors 
p OR / 
Exp (B) 
p OR / 
Exp (B) 
p OR / 
Exp (B) 
Age (years) < 0.001 1.05* < 0.001 1.05* < 0.001 1.05* 
Race (RC = Caucasian) < 0.001 6.18* < 0.001 6.19* < 0.001 6.16* 
Sex (RC = Male) 0.96 0.99 0.82 0.97 0.94 1.00 
Years of Schooling 0.047 1.05* 0.09 1.04 0.09 1.04 
Lifestyle Factor 
(Categorical, RC = No) 
0.30 1.15 0.26 1.15 0.78 0.96 
Study Group (RC = 
Schizophrenia) 
< 0.001  < 0.001  < 0.001  
1st Degree Relatives < 0.001 0.18* < 0.001 0.18* < 0.001 0.18* 
Controls < 0.001 0.21* < 0.001 0.19* < 0.001 0.20* 
RC = Reference Category 
(B) p = Significance for the regression coefficient associated with the independent variable 
OR / Exp (B) = Odds Ratio derived from exponentiation of the regression coefficient.  
*=Odds Ratios that did not include the null value (‘1’). 
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Age, race, years of schooling, and study group membership were significant risk factors 
for hypertension for the analysis that included smoking as the lifestyle factor.  Hypertension was 
associated with increasing age, African-American race, higher years of schooling and diagnosis 
of schizophrenia but not with sex, or any of the lifestyle factors.  First degree relatives and 
controls had a lower likelihood of having hypertension as compared to patients with 
schizophrenia.  Analyses for alcohol use and marijuana use also showed significant relations 
between hypertension and age, race and study group membership, but not for years of schooling.  
The strength of significant risk factors was confirmed in the reduced model using stepwise 
regression with backwards elimination (data not shown). Separate analyses within each study 
group and a simultaneous regression using all the lifestyle factors together also confirmed that 
none of the lifestyle factors had any association with hypertension (data not shown). 
4.5 DISCUSSION 
This study compared the associations between lifestyle factors such as smoking, alcohol, and 
marijuana use and diabetes and hypertension in patients with schizophrenia, their 1st degree 
relatives, and contemporaneously enrolled healthy controls.  Higher rates for diabetes and 
hypertension in patients with schizophrenia in this sample have previously been reported (Brar, 
Paper 2).  This study also found higher rates of smoking, alcohol and marijuana in patients with 
schizophrenia compared with healthy controls.  The National Survey on Drug Use and Health 
(NSDUH), an annual survey commissioned by the Substance Abuse and Mental Health Services 
Administration (SAMHSA), found that the rates of (current) smoking steadily decreased from 
26% to 23% in the period between 2002 to 2010 (NSDUH, 2012).  The rates of smoking in the 
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control group in the study are two-fold higher than NSDUH rates as the study sample included 
current and past smokers.  The rates of smoking in patients with schizophrenia were three-fold 
higher than the rates in the NSDUH survey.  The NSDUH survey also showed that 
approximately half (51.8%) of all individuals surveyed were current drinkers.  These rates are 
higher than the rates observed among healthy controls in the study sample (38.3%) as only those 
subjects who “drank at least once a week for six months or more” were classified as alcohol 
drinkers.  In the study sample, the rate of alcohol use in patients with schizophrenia was 
approximately 35% higher than the rates in controls.  The rates for lifetime use of marijuana in 
the NSDUH survey range from 43% in 18 year old subjects to 56% in subjects who were in their 
mid fifties.  These are in close approximation to the lifetime rates observed among controls in the 
study sample (54.8%).  The rates of marijuana use in patients with schizophrenia were 
approximately 25% higher than the rates in controls in the study sample.  The rates of smoking 
and marijuana use in patients with schizophrenia were also significantly higher than the rates in 
their 1st degree relatives.  The rates for alcohol use however did not differ significantly between 
patients and their 1st degree relatives.  The lack of differences may have resulted from commonly 
inherited genetic variants by patients with schizophrenia and their 1st degree relatives that are 
linked to alcohol use (Ribbe et al., 2011).  Studies in twins have shown that individuals with 
schizophrenia and alcoholism have a genetic predisposition to the development of both disorders 
(Kendler, 1985). 
Smoking and alcohol use were not associated with diabetes in any of the study groups or 
in the combined sample.  However, an inverse association between marijuana use and diabetes 
was found in the unadjusted analysis that did not correct for socio-demographic factors.  This 
inverse association was not observed in any single study group but only in the combined sample 
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that corrected for study group membership.  It is important to note that this association was not 
observed after adjusting for socio-demographic factors in the multivariate model.   
An inverse association between marijuana use and diabetes was reported in a recent study 
that examined the NHANES-III (Rajavashisth et al., 2012).  The authors argued that 
cannabinoids, bioactive components of marijuana, have demonstrable anti-inflammatory 
properties that may decrease the incidence of diabetes through their action on prostaglandins and 
COX-2 (Partignani et al., 2005).  In animal models, cannabinoids have been shown to have a 
beneficial effect against atherosclerosis and complications of diabetes (Rajesh et al., 2007).  This 
inverse association merits further investigation and replication in an independent sample. 
Alcohol use was not associated with hypertension in any of the study groups or in the 
combined sample.  Marijuana use showed an inverse association with hypertension in 1st degree 
relatives, but not in the other study groups, or in the combined sample, or in the multivariate 
model.  An explanation for this inverse association is not readily available.  It could have 
spuriously emerged from a type-1 error as the analyses were not corrected for multiple 
comparisons.  Smoking was associated with a higher likelihood of hypertension in patients with 
schizophrenia, and in the combined sample that corrected for study group membership but not in 
the multivariate model.  An association between smoking and hypertension has been shown 
earlier (Rosen et al., 2006).  Furthermore, it is not surprising that this association was also 
observed in patients with schizophrenia as this sample is known to smoke heavily and draw 
higher levels of nicotine from cigarettes (de Leon et al., 1995). 
As stated earlier, multivariate analyses that included socio-demographic factors failed to 
show associations between any of the lifestyle factors and diabetes or hypertension.  Several 
reasons could account for the lack of relationship between lifestyle factors and diabetes or 
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hypertension.  The model does not include information on atypical antipsychotic use or adiposity 
that may account for major factors responsible for the development of diabetes or hypertension.  
Furthermore, it is possible that the multivariate models examined may have been over-fitted with 
too many independent factors.  However, this was not the case as step-wise regression with both 
‘forward selection’ and ‘backwards elimination’ failed to show any associations with any of the 
lifestyle factors.  It is also possible that the effect size, i.e. the proportion of variance explained 
by another variable or set of variables (in this case, age and race) is so large that the addition of 
other risk factors, for example lifestyle factors, does little to improve the model.  Lack of 
associations between lifestyle factors and diabetes and hypertension may also have resulted from 
the characteristic of the variable used for the analyses.  For example, alcohol has a known U-
shaped relationship with cardiovascular diseases.  Low to moderate levels of alcohol 
consumption are beneficial (cardio-protective), whereas heavy use is detrimental.  The 
categorical variable used in the analyses essentially combined all levels of alcohol consumption, 
thus reducing its sensitivity.    
The weaknesses of the study include the cross-sectional nature of the data that precludes 
examination of causality and characterization of diabetes and hypertension by self-report that can 
result in under-estimation of the outcome (Elliott and Huizinga, 1989).  Furthermore, as 
mentioned earlier, patients with schizophrenia and non-psychiatric controls who had alcohol or 
substance abuse and/or dependence were excluded from enrollment in the genetic studies, 
whereas 1st degree relatives of probands were not. This differential truncation of alcohol and 
marijuana use data for two of the three groups used for this study is likely to have affected the 
internal validity of the findings. Another important weakness of this study is the lack of validity 
of selected items chosen for characterizing alcohol and marijuana use.  The psychometric 
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properties of the items chosen from DIGS for this study have not been established.  Lastly, as 
mentioned earlier, the study does not address other important mediators that may explain the 
relationship if any, between lifestyle factors and diabetes and hypertension.  For example, 
obesity or atypical antipsychotic use may mediate the response between alcohol use and diabetes, 
but in the absence of body weight and medication use data, this could not be examined.  The 
strengths of this study include uniformity of data collection, diagnostic case ascertainment, 
contemporaneously recruited controls, and a large and heterogeneous sample.  
These limitations notwithstanding, the high rates of smoking, alcohol and marijuana use 
observed in this sample should provide caution to healthcare providers for allocating services for 
the management of these risk factors.  Smoking, alcohol and marijuana use in patients with 
schizophrenia are associated with a wide range of poor clinical and social outcomes (Drake et al., 
1989; Drake et al., 1990).  Although associations of these lifestyle factors with diabetes and 
hypertension were not found, other associations, such as smoking with chronic pulmonary 
obstructive disease in patients with schizophrenia, are well-established (Oud and Meyboom-
deJong, 2009).  Addressing these lifestyle risk factors proactively will go a long way in meeting 
the goals for the SAMHSA “10 X 10 Wellness Campaign” to increase life expectancy by 10 
years in 10 years (10 X 10) for people with mental illness. 
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                                                5.0  GENERAL DISCUSSION 
Medical comorbidities such as cardiovascular diseases, diabetes, pulmonary and infectious 
diseases are implicated in the shortened lifespan in patients with severe mental illnesses like 
schizophrenia and related disorders, such as schizoaffective disorder and psychotic disorder, not 
otherwise specified.  Much of the research in this area has focused on assessing the prevalence of 
obesity and obesity-related illnesses in patients with schizophrenia with respect to treatment with 
psychotropic antipsychotic medications.  There is however a paucity of systematic research on 
other factors, namely socio-demographic and lifestyle factors, which may also contribute to the 
development of these comorbidities in these patients.  Furthermore, it is not known how the risk 
afforded by these factors may be modified by the genetic predisposition associated with several 
medical comorbidities.  Specifically, it is not known how shared genetic and environmental 
factors within families of patients with schizophrenia, for example common socio-demographic 
factors, may modify the genetic predisposition for the development of medical illnesses.  It is 
also not known whether the risk for developing medical comorbidities in patients with 
schizophrenia is higher than the risk in their first degree relatives who do not have a mental 
illness.   
This dissertation evaluated the association between socio-demographic and lifestyle 
factors with diabetes and hypertension in patients with schizophrenia, their non-psychiatric first 
degree relatives, and contemporaneously recruited non-psychiatric controls.  The dissertation 
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also included a systematic review of published studies that examined the associations between 
socio-demographic and lifestyle factors and diabetes and hypertension in patients with 
schizophrenia and related disorders.  The systematic review was carried out using established 
methodology. A cross-sectional study using pooled data derived from the Diagnostic Interview 
for Genetic Studies (DIGS) was examined.  The data for these analyses were derived from four 
large NIMH-funded genetic studies in patients with schizophrenia. These studies investigated the 
genetic basis for schizophrenia by enrolling patients with schizophrenia and related disorders, 
their affected (psychiatric) and unaffected (non-psychiatric) first degree relatives, and unrelated 
non-psychiatric controls from the same geographic areas.  The DIGS was used to obtain socio-
demographic and clinical information for diagnostic formulation of all study participants 
including the proband, or index case (patient with schizophrenia), their psychiatrically ill and 
non-psychiatric first degree relatives, and unrelated non-psychiatric controls.  In addition to 
psychopathology, the DIGS also elicited information about medical comorbidities.  This uniform 
methodology facilitated the pooling of data in order to examine factors associated with medical 
comorbidities in all groups of interest.  The associations between socio-demographic and 
lifestyle factors and diabetes and hypertension were compared in patients with schizophrenia, 
their non-psychiatric first degree relatives, and unrelated non-psychiatric controls. 
5.1 SUMMARY OF FINDINGS 
The systematic review based on 26 studies showed a strong effect of age and African-American 
race on the prevalence of diabetes.  Age was also associated with the metabolic syndrome, 
although the effect of race was equivocal.  Sex was an effect modifier for diabetes and the 
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metabolic syndrome in some, but not all, studies with higher rates in females.  Studies of 
hypertension were too few to reach meaningful conclusions.  Other social and lifestyle factors 
were either rarely or never examined, which prohibited an assessment of attributable risk. 
The first cross-sectional study showed higher rates of diabetes and hypertension in 
patients with schizophrenia compared with unrelated non-psychiatric controls.  While the rates of 
hypertension in patients with schizophrenia were also higher than the rates in their 1st degree 
relatives, the rates of diabetes did not differ between these two groups.  Multivariate models that 
included age, race, sex, years of schooling, marital status, occupational status, and living 
arrangement as independent risk factors showed that only age and race were significant risk 
factors for diabetes and hypertension.  The higher risks for diabetes and hypertension in patients 
with schizophrenia compared to their 1st degree relatives and unrelated non-psychiatric controls 
were also confirmed in the multivariate analyses. 
The second cross-sectional study showed higher rates of smoking, alcohol and marijuana 
use in patients with schizophrenia compared with unrelated non-psychiatric controls.  The rates 
of smoking and marijuana use in patients were also higher than the rates in their 1st degree 
relatives.  Multivariate analyses that included age, race, sex and years of schooling failed to show 
any significant associations for smoking, alcohol or marijuana use with diabetes or hypertension.   
Only established non-modifiable factors, namely age and race, were confirmed as risk 
factors for diabetes and hypertension in the systematic review and cross-sectional study.  The 
analyses confirmed the high rates of diabetes and hypertension in patients with schizophrenia 
and the high rates of lifestyle factors, namely smoking, alcohol and marijuana use, in this 
population.  However, the attributable risk of other socio-demographic factors and lifestyle 
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factors (smoking, alcohol and marijuana use) on the prevalence of diabetes or hypertension was 
not demonstrated.  
The dissertation confirms the need for developing services for minority, mainly African-
American, patients with schizophrenia in order to reduce the disease burden and mortality 
associated with co-morbid diabetes and hypertension.  The strong association with age also 
emphasizes the need for preventative services for patients early in the course of schizophrenia 
who have not yet developed diabetes or hypertension.  
5.2 FUTURE DIRECTIONS 
The associations of diabetes and hypertension with increasing age and African-American race 
underscore the need for primary prevention of these disorders in an already disadvantaged 
population.  It is important for clinicians and other care providers to have a heightened awareness 
of the risk for diabetes and hypertension in minority race patients.  Interventions, both 
pharmacological and behavioral, must be instituted in this vulnerable group of patients early in 
the course of the psychiatric illness before diabetes and hypertension develop. 
 The bivariate associations between lifestyle factors, such as smoking, alcohol and 
marijuana use, and diabetes and hypertension deserve an independent examination. These 
associations could be examined in national administrative and claims databases, or in studies that 
have enrolled large numbers of patients with schizophrenia.  Secondary data analyses examining 
the association between lifestyle factors and diabetes and hypertension in the CATIE 
(Comparative Antipsychotic Trial of Intervention Effectiveness) study would be an ideal starting 
point. 
 120 
          BIBLIOGRAPHY 
Allison, D. B., and Fontaine, K.R. (1999). The distribution of body mass index among 
individuals with and without schizophrenia. Journal of Clinical Psychiatry, 60, 215–220. 
Baptista, T. (1999). Body weight gain induced by antipsychotic drugs: mechanisms and 
management. Acta Psychiatrica Scandinavica, 100, 3-16. 
Beebe, L.H., Burk, R., McIntyre, K.B., Smith, K., Velligan, D., Resnick, B., Tavakoli, A., 
Tennison, C., and Dessieux, O. (2009). Motivating Persons with Schizophrenia to 
Exercise: Rationale and Design. Clinical Schizophrenia and Related Psychoses, 3(2), 
111-116. 
Brar, J. S., Ganguli, R., Pandina, G., Turkoz, I., Berry, S., and Mahmoud R. (2005). Effects of 
behavioral therapy on weight loss in overweight and obese patients with schizophrenia or 
schizoaffective disorder. Journal of Clinical Psychiatry, 66, 205–212. 
Brown, S., Birtwhistle, J., Roe, L., and Thompson, C. (1999). The unhealthy lifestyle of people 
with schizophrenia.  Psychological Medicine, 29, 697-701. 
Carney, C.P., Jones, L. and Woolson, R.F. (2006). Medical comorbidity in women and men with 
schizophrenia: a population-based controlled study. Journal of General Internal Medicine, 
21, 1133-1117. 
 121 
Chwastiak, L. A., Rosenheck, R. A., McEvoy, J. P., Stroup, T. S., Swartz, M. S., Davis, S. M., 
and Lieberman, J. A. (2009). The impact of obesity on health care costs among persons 
with schizophrenia. General Hospital Psychiatry, 31 (1), 1-7. 
Cohen, C. I., (1993).  Poverty and the course of schizophrenia: Implications for research and 
policy. Hospital and Community Psychiatry, 44, 951-958.  
Cohen, D., Dekker, J.J., Peen, J., deWied, G. (2006) Prevalence of diabetes mellitus in chronic 
schizophrenic patients in relation to long-term antipsychotic treatment. European 
Neuropsychopharmacology, 16, 187-94. 
Corrao, G., Bagnardi, V., Zambon, A., and La Vecchia, C. (2004). A meta-analysis of alcohol 
consumption and the risk of 15 diseases . Preventive Medicine, 38, 613–619. 
Dixon, L., Postrado, L., Delahanty, J., Fisher, P., and Lehman, A. (1999). The association of 
medical comorbidity in schizophrenia with poor physical and mental health. Journal of 
Nervous and Mental Disease, 187, 496-502. 
Dixon, L., Weiden, P., Delahanty, J., Goldberg, R., Postrado, L., Lucksted, A., and Lehman A. 
(2000). Prevalence and correlates of diabetes in national schizophrenia samples. 
Schizophrenia Bulletin, 26, 903-912. 
Elliott, D. S., and Huizinga, D. (1989). Improving self-report measures of delinquency. In M. 
Klein (Ed.), Cross-national research in self-reported crime and delinquency (pp. 155-
186). Boston: Kluwer Academic Publishers. 
Felker, B., Yazel, J. J., and Short, D. (1996). Mortality and medical comorbidity among 
psychiatric patients: A review. Psychiatric Services, 47, 1356–1363. 
Fiel, S. B. (1996). Chronic obstructive pulmonary disease mortality and mortality reduction. 
Drugs, 52, 55-61. 
 122 
Folsom, D. P., McCahill, M., and Bartels, S.J. (2002). Medical Comorbidity and Receipt of 
Medical Care by Older Homeless People With Schizophrenia or Depression, Psychiatric 
Services, 53, 1456-1460. 
Folsom, D. P., McCahill, M., and Bartels, S.J. (2002). Medical Comorbidity and Receipt of 
Medical Care by Older Homeless People with Schizophrenia or Depression, Psychiatric 
Services 53, 1456-1460. 
Hennekens, C.H., Hennekens, A., Hollar, D., and Casey D.E. (2005). Schizophrenia and 
increased risk of cardiovascular disease. American Heart Journal, 150,1115-1121. 
Jayanthi, S., Buie, S., Moore, S., Herning, R. I., Better, W., Wilson, N. M., ... & Cadet, J. L. 
(2008). Heavy marijuana users show increased serum apolipoprotein C-III levels: 
evidence from proteomic analyses. Molecular Psychiatry, 15(1), 101-112. 
Kane, I., Lee, H., Sereika, S., and Brar, J. S. (2012). Feasibility of pedometers for adults with 
schizophrenia: a pilot study. Journal of Psychiatric Mental Health Nursing, 19, 8-14. 
Kaplan, G.A., Keil, J.E. (1993). Socioeconomic factors and cardiovascular disease: a review of 
the literature. Circulation. 88, 1973-98. 
Kent, S., Fogarty, M., and Yellowlees, P. (1995). Heavy utilization of inpatient and outpatient 
services in a public mental health service. Psychiatric Services, 46, 1254–1257. 
Kinon, B. J., Basson, B. R., and Gilmore, J. A. (2001). Long-term olanzapine treatment: weight 
change and weight-related health factors in schizophrenia. Journal of Clinical Psychiatry, 
62, 92-100. 
Kittles, R. A., and Weiss, K. M. (2003). Race, ancestry and genes: Implications for Defining 
Disease Risk. Annual Review of Genomics and Human Genetics, 4, 33-67. 
 123 
Kraepelin, E. (1919). Manic-Depressive Insanity and Paranoia (trans. R. M. Barclay). Edinburgh: 
Livingstone. 
Mokdad, A.H., Ford, E.S., and Bowman, B.A. (2003). Prevalence of obesity, diabetes, and other 
obesity-related health risk factors. Journal of the American Medical Association, 289, 76-
79.  
Munk-Jorgensen, P., Mors, O., Mortensen, P.B., and Ewald, H. (2000). The schizophrenic 
patient in the somatic hospital. Acta Psychiatrica Scandinavica, 102, 96-99. 
Nasrallah, H. (2003). A review of the effect of atypical antipsychotics on weight. 
Psychoneuroendocrinology, 28(Suppl 1), 83–96. 
Newman, S. C., and Bland, R. C. (1991) Mortality in a cohort of patients with schizophrenia: a 
record linkage study. Canadian Journal of Psychiatry, 36, 239-245. 
Nurnberger, J., Blehar, M.C., Kaufmann, C.A., York-Cooler, C., Simpson, S.G., Harkavy-
Friedman, J., Severe, J.B., Malaspina, D. and Reich, T. (1994). Diagnostic interview for 
genetic studies. Rationale, unique features, and training. NIMH Genetics Initiative. 
Archives of GeneralPsychiatry, 51, 849-859. 
Ornish, D.M., Brown, S.E., Scherwitz, L.W., Billings, J.H., Armstrong, W.T., Ports, T.A., 
McLanahan, S.M., Kirkeeide, R.L., Brand, R.J., and Gould, K.L. (1990). Can lifestyle 
changes reverse coronary heart disease? The Lifestyle Heart Trial. Lancet, 336, 129 –133. 
Paeratakul, S., Lovejoy, J. C., Ryan, D. H., and Bray, G. A. (2002). The relation of gender, race 
and socioeconomic status to obesity and obesity comorbidities in a sample of US adults. 
International Journal of Obesity, 26, 1205-1210. 
Parks, J., Svendsen D., Singer, P., Foti, M. (2006). Morbidity and mortality in people with 
serious mental illness.  National Association of State Mental Health Program Directors 
 124 
(NASMHPD) Medical Directors Council. 
http://www.nasmhpd.org/general_files/publications/med_directors_pubs/Mortality%20an
d%20Morbidity%20Final%20Report%208.18.08.pdf (accessed on October 17, 2012). 
Parnas, J., Cannon, T.D., Jacobsen, B., Schulsinger, H., Schulsinger, F., and Mednick, S. (1993). 
Lifetime DSM-III-R diagnostic outcomes in the offsprings of schizophrenic mothers. 
Archives of General Psychiatry, 50, 707-714. 
Redelmeier, D. A., Tan, S. H., and Booth G. L. (1998). The Treatment of Unrelated Disorders in 
Patients with Chronic Medical Diseases, New England Journal of Medicine, 338, 1516-
1520. 
Ryan, M. C. M., and Thakore, J.H. (2002). Physical consequences of schizophrenia and its 
treatment: the metabolic syndrome. Life Sciences, 71, 239 -257. 
Sherry, B., Blanck, H. M., Galuska, D. A. Pan, L., Dietz, W. H. and Balluz, L. (2010).  Vital 
Signs: State-specific Obesity Prevalence among Adults — United States, 2009. Morbidity 
and Mortality Weekly Report. 59, 951-955.  
Strassnig, M., Brar, J. S., Ganguli, R. (2003). Nutritional assessment of patients with 
schizophrenia: a preliminary study. Schizophrenia Bulletin, 29, 393–397. 
Zerhouni, E. (2003). The NIH Roadmap. Science, 302 (5642), 63-72. 
 
